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SUMMARY 
This study describes: 
 The UPLC-MS/MS analyses and quantification of novel 5α-reduced steroids using
response factors.
 The kinetic characterisation of human steroid 5α-reductase type 1 (SRD5A1),
expressed in HEK-293 cells, towards 11OHA4 and 11OHT and their keto derivatives
by progress curve analysis.
 The subcloning, transformation and functional expression of SRD5A1 in the yeast
expression system, P. pastoris.
 The conversion of 11OHA4 and 11OHT and their keto derivatives by SRD5A1
expressed in P. pastoris.
 The endogenous enzymatic activity in P. pastoris towards the 5α-reduced metabolites
in the 11OHA4- and alternate 5α-dione pathways.
 The potential application of P. pastoris as a biocatalyst in the production of 5α-
reduced C19 steroids.
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iv 
OPSOMMING 
 
Hierdie ondersoek beskryf: 
 Die UPLC-MS/MS analise en kwantifisering van nuut-ondekte 5α-gereduseerde 
steroïede met behulp van responsfaktore. 
 Die kinetiese karakterisering van menslike steroïed 5α-reduktase tipe 1 (SRD5A1), 
uitgedruk in HEK-293 selle, vir 11OHA4 en 11OHT en hul ketoderivate deur middel 
van progressiekurwe-analise.  
 Die subklonering, transformasie en funksionele uitdrukking van SRD5A1 in die gis 
P. pastoris. 
 Die omsetting van 11OHA4 en 11OHT en hul ketoderivate deur SRD5A1 uitgedruk in 
P. pastoris. 
 Die omsetting van 5α-gereduseerde steroïede in die 11OHA4 en alternatiewe 5α-dioon 
paaie deur  endogene ensieme in P. pastoris 
 ‘n Ondersoek na die  toepassing van die gisuitdrukkingstelsel as ‘n moontlike OR 
potensiële biokatalis vir die produksie van 5α-gereduseerde C19 steroïede. 
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Chapter 1 
STEROID 5α-REDUCTASE AND ITS ROLE IN PROSTATE CANCER 
1.1 Prostate 
The prostate is a male accessory sex organ comprised of stromal components surrounding the 
urethra and found just below the bladder as illustrated in figure 1.1 (1). The primary function 
of the prostate is to contribute, together with the seminal vesicles, to the ejaculate by the 
synthesis and secretion of proteins and fluid. The prostate requires nutrients, oxygen and 
androgen stimulation for normal growth, development and function. Androgens are a class of 
steroid hormones required for the development and maintenance of male sexual 
characteristics (2). The most abundant androgen in males, testosterone (T), is synthesized 
primarily in the Leydig cells of the testes (3). The production and secretion of T from the 
testes is under the endocrine control of the luteinizing-hormone-releasing hormone (LHRH) 
and luteinizing hormone (LH) axis (4). Mediation of androgenic effects are by way of the 
androgen receptor (AR) which is a ligand-dependant transcription factor and a member of the 
nuclear receptor family (5). While T is the most abundant androgen in circulation, it is 
converted to 5α-dihydrotestosterone (DHT) in peripheral tissue, such as the prostate, by the 
enzyme steroid 5α-reductase (SRD5A). DHT is the most potent natural androgen (6). The 
relative potency of T for activation of wildtype AR is 0.1-1 nM while that of DHT is 0.01-
0.1 nM (7, 8).  
 
Figure 1.1 Location of prostate relative to the bladder and urethra (Reproduced from http://www.cancer.gov) 
In the absence of androgens the AR is bound to heat-shock proteins, HSP70 and HSP90, as 
illustrated in figure 1.2. The AR proteins are prohibited from binding to DNA in the absence 
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of ligand rendering the receptor inactive. Ligand binding to AR releases the receptor from 
heat shock proteins, facilitating AR homodimerization, rapid nuclear translocation, post-
translational modification and receptor stabilization (9, 10). Rapid entry into the nucleus is 
achieved by ligand bound AR homodimers. These homodimers bind to specific DNA-
sequences called androgen responsive elements (AREs). Binding of the AR homodimers, 
together with a number of cofactors, to an ARE initiates the transcription of androgen 
regulated genes (11). 
One such gene is kallikrein-3, which is better known as prostate specific antigen (PSA). PSA 
is a protease which assists in liquefying semen to enable sperm movement to the ovum (12). 
During prostate cancer and other prostate diseases PSA leaks into the surrounding stroma and 
vasculature due to the disruption of the basal membrane and basal epithelial layer. Serum 
PSA levels are therefore used as a diagnostic marker for prostate diseases (13).  
 
Figure 1.2 Androgen dependent gene regulation. After entering the prostate epithelial cell T is converted to 
DHT by SRD5A. DHT binds to the AR resulting in a conformational change which facilitates the dissociation of 
the HSPs. Two ligand-bound ARs form a homodimer which enters the nucleus and binds to an ARE to initiate 
transcription. (Reproduced from (10)) 
The AR axis is vital to the maintenance of balance between proliferation and apoptosis, 
resulting in no net growth of the adult prostate while cells are continuously replaced (14). 
Without androgens the prostate gland would atrophy (15). The importance of DHT in the 
development of the prostate is evident in individuals with the inherited 5α-reductase type 2 
(SRD5A2) deficiency, characterised by atrophied prostate glands (16). Similarly, the  
dependence of the prostate on androgens is clearly demonstrated by surgical castration and 
adrenalectomy removing all sources of androgen and resulting in atrophy of the prostate (17). 
In addition to being essential to the normal functioning of the prostate, androgens also play a 
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significant role in the pathogenesis of benign prostatic hyperplasia (BPH) and prostate cancer. 
The role of androgens in prostate cancer has been a subject of interest since the mid-20
th
 
century (14).  
1.2 Prostate Cancer 
Globally, prostate cancer is the second most diagnosed cancer in men and is the sixth leading 
cause of cancer-related deaths, with a fatality rate of 63% (18, 19). Prostate cancer has been 
shown to be more prevalent in developed countries, though this could be due to under-
reporting in developing countries. In the United States of America, it is the second leading 
cause of death due to cancer amongst men (20, 21). African-American men have the highest 
incidence of prostate cancer in the world with a 50-fold higher incidence of prostate cancer 
than Japanese and Chinese men (22, 23). According to the national cancer registry, prostate 
cancer is the most common cancer affecting men in South Africa, with at least 4000 cases 
diagnosed each year (24).  
Charles Brenton Huggins was awarded the Nobel Prize in Physiology in 1966 for discovering 
that the prostate is dependent on androgens. He demonstrated that castration led to a decrease 
in the prostates size and weight (25). Based on this discovery the first line in treating 
advanced localised prostate cancer is the inhibition of testicular T production, which is known 
as androgen deprivation therapy (ADT) (25, 26). This is accomplished by either surgical 
(orchiectomy) or chemical castration. Chemical castration is accomplished using LHRH 
agonist or antagonists, which both lead to the inhibition of T biosynthesis by the testes (27). 
Another therapeutic strategy is the use of AR antagonists, which would normally be 
administered along with ADT for a synergistic effect (28).  
Apoptotic regression of both benign and malignant prostate epithelial cells is triggered by  
ADT (29). A decrease in PSA levels as well as objective and symptomatic responses are 
observed in over 80% of patients treated with ADT (29). This treatment initially yields good 
results, but in many cases AR signalling pathways are reactivated after a 2-3 year remission 
period characterised by an increase in PSA expression (26). The recurring cancer is then 
termed castration resistant prostate cancer (CRPC) (30).  
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1.3 Castration Resistant Prostate Cancer 
1.3.1 Castration resistant prostate cancer development 
Despite the initial remission which is observed following ADT, the progression to CRPC is 
extremely common (31). This deadly form of prostate cancer is proposed to be the result of 
the selective pressure imposed by ADT favouring the growth of androgen-insensitive cells 
(32–34). However, the reactivation of the androgen axis is characterised by the up-regulation 
of PSA expression (35). Genome- wide expression profiling, has revealed that most androgen 
gene networks are reactivated during CRPC progression (36–38). Furthermore, recent clinical 
studies with the CYP17A1 inhibitor, abiraterone (39, 40) and the AR antagonist enzalutimide 
(41) confirm that CRPC remains androgen dependent.   
Mechanisms implicated in the reactivation of the AR axis following ADT (circulating T < 20 
ng/dL) include adaptations such as AR amplification, expression of AR splice variants, AR 
mutations and the activation of AR complex via cross-talk with other signalling pathways (42). 
While these mechanisms increase the sensitivity of the AR axis, they still required the 
presence of AR ligand (31). Tumours displaying resistance to castration are characterised by 
elevated intratumoural androgen levels which are high enough to elicit a response from the 
AR (8, 42). While surgically castrated males demonstrate a 90-95% drop in circulating T 
levels, intraprostatic DHT levels have been shown to decrease by only 50% (2, 36, 37). An 
explanation for this observation is that T is not the only precursor to DHT. The adrenal gland 
produces androgen precursors, dehydroepiandrosterone (DHEA), androstenedione (A4) and 
11β-hydroxyandrostenedione (11OHA4) which are all released into circulation (43–45). 
Recent studies have shown that these weak adrenal androgen precursors can be metabolised in 
CRPC tissue to yield active androgens which reactivate the AR axis (46–51). Enzymes such 
as AKR1C3, SRD5A1 and HSD3B2 are required for the metabolism of adrenal androgen 
precursors and have been shown to be upregulated during CRPC (31). A number of androgen 
biosynthetic pathways have been suggested to play a role in CRPC. These include the 
classical pathway, the alternative 5α-androstenedione (5α-dione) pathway and the newly 
discovered 11OHA4 pathway (26, 46, 47).  
1.3.2 Androgen biosynthesis by the testes and adrenal cortex 
Five enzymes stand between the conversion of cholesterol to T and DHT, these include: 
cytochrome P450 side-chain cleavage (CYP11A1), cytochrome P450 17α-hydroxylase/17,20-
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lyase (CYP17A1), 3β-hydroxysteroid dehydrogenase/∆5,4 isomerase (HSD3B), 17β-
hydroxysteroid dehydrogenase (HSD17B) and steroid 5α-reductase (SRD5A).  
The first step in the production of all steroid hormones involves the side-chain cleavage of 
cholesterol catalysed by CYP11A1 which is found in the inner mitochondrial membrane (52) 
(Fig. 1.3). Cholesterol is transported from the outer mitochondrial membrane to the inner 
membrane by the action of the protein StAR (53). Following the conversion of cholesterol to 
pregnenolone (PREG) in the testes, the product is further metabolized by the 17α-hydroxylase 
activity of CYP17A1 yielding 17α-hydroxypregnenolone (17OH-PREG). 17OH-PREG is 
subsequently catalysed by the 17,20-lyase activity of CYP17A1 to produce the C19 steroid, 
DHEA. DHEA is  converted to A4 by HSD3B2 and A4 is subsequently converted to T by 
HSD17B3 (53).   
The Leydig cells, found in the testes, are responsible for 90-95% of the production of 
circulating T in males. (15). LHRH from the hypothalamus stimulates the release of LH from 
anterior pituitary gland which in turn stimulates T production by the Leydig cells. A negative 
feedback system regulates the production of T as it inhibits the release of LHRH to maintain 
normal circulating levels. Biosynthesis of T (Fig 1.3) takes place continually as the Leydig 
cells cannot store androgens. T is secreted into circulation with only 1-2% being in free form 
while the remainder is either bound to albumin (±54%) or sex hormone binding globulin 
(±44%) (15).  
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Figure 1.3 Production of T by the Leydig cells. Reproduced from (53).  
T is also produced in the adrenal, accounting for 5-10% of the steroid in circulation. The 
adrenal’s contribution under normal physiological conditions is, however, insignificant 
compared to the levels produced by the Leydig cells. The adrenal cortex is divided into three 
distinct zones, the zona glomerulosa, the zona fasiculata and the zona reticularis. These three 
zones produce mineralocorticoids, glucocorticoids and androgen precursors, respectively. The 
type of steroid produced by each zone is determined by the specific enzymes expressed in the 
zones. Steroidogenesis in the zona reticularis is very similar to that in Leydig cells. In humans 
a distinct zona reticularis forms during adrenarche which occurs between age 6-8 and is 
marked by the increase in synthesis and secretion of adrenal androgen precursors such as 
DHEA and DHEA-S, as a result of the maturation of the zona reticularis. During adrenarche 
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the expression profile of key steroidogenic enzymes are altered in the developing zona 
reticularis in order to ensure adrenal androgen production. The expression of cytochrome b5, a 
small hemoprotein which enhances the 17,20-lyase activity of CYP17A1 by an allosteric 
mechanism, is increased thus increasing DHEA production (54, 55). In contrast, HSD3B2 
expression decreases during adrenarche, preventing the production of mineralocorticoids and 
glucocorticoids (55).  
In the zona reticularis, as in the Leydig cells steroidogenesis involves the conversion of 
cholesterol to PREG by CYP11A1, followed by the 17α-hydroxylase and subsequent 17,20-
lyase activities of CYP17A1 yielding DHEA (fig. 1.4), In the zona reticularis a large 
proportion of the resulting DHEA is sulfated by SULT2A1 to produce DHEAS which is 
released into circulation (55). DHEA itself is also released into circulation. DHEA is, 
however, also converted to A4 by HSD3B2 and is released into circulation. A4 can also serve 
as the substrate for the adrenal enzyme CYP11B1, which is responsible for the hydroxylation 
of the substrate at C11 yielding 11OHA4 (44) as well as AKR1C3 which reduces A4 to T.  
Xing and colleagues have shown, while determining the effects of ACTH on steroid profiles 
in human adrenal cells, that the androgen precursors A4 and 11OHA4 are two of the most 
abundant steroids produced under basal conditions. The production of these steroids is further 
increased after incubation with ACTH (56). Using UPLC-MS/MS analysis our research group 
was able to quantify steroid intermediates and end products of adrenal steroidogenesis. 
11OHA4, was shown to be one of the major metabolites produced in H295R (human adrenal 
carcinoma) cells. Upon forskolin stimulation, the basal levels of 11OHA4 was shown to 
increase 4.5-fold to 390 nM (44). Forskolin stimlates steroidogenesis in H295R cells which 
are insensitive to ACTH. More recently, Rege et al. showed that 11OHA4 is one of the most 
abundant C19 steroids detected in the adrenal vein (43–45). Levels of 11OHA4 were found to 
be 2-fold higher than those of A4, both pre- and post-ACTH stimulation. 11OHA4 levels 
increased to 811 nM after ACTH stimulation (table 1.1). The levels of 11OHA4 were ~100-
fold higher (under both basal conditions and ACTH stimulation) than T and its derivatives. 
Low levels of 11KA4, 11OHT and 11KT were also detected under both basal and stimulated 
conditions (table 1.1) (45). Investigations into the catalytic activity of CYP11B1 and 
CYP11B2, showed that both enzymes are able to catalyse the hydroxylation of T and A4. 
Both HSD11B1 and 2 interconvert 11OHT and 11OHA to 11KT and 11KA4 (57), however, 
further investigation is needed to establish whether 11KA4 and 11KT is catalysed from 
11OHA4 and 11OHT by HSD11B2 in the adrenal. AKR1C3 and low levels of HSD11B1, 
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HSD11B2 and HSD17B3 (mRNA transcripts) have been shown to be expressed in the adrenal 
gland, are responsible for the low levels of 11OHT 11KT and 11KA4 detected in adrenal vein 
samples (45).  
 
Table 1.1 Primary androgens produced and secreted by the adrenal after ACTH stimulation. Steroids are 
displayed in order of the most to the least abundant as detected in human adrenal vein samples. Modified from 
(45). 
Steroid metabolite Post-ACTH (nmol/L) Fold Change from basal 
DHEAS 18 266 ± 3842 4.8 
DHEA 2659 ± 666 21.2 
11OHA4 811 ± 260 5.2 
A4 585 ± 199 7.4 
Androstenediol 20.7 ± 6.46 18.0 
T 5.71 ± 1.42 7.3 
11KA4 3.18 ± 0.63 3.2 
11OHT 2.62 ± 0.74 5.5 
11KT 0.49 ± 0.11 1.3 
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Figure 1.4 Adrenal androgen biosynthesis. (Modified and reproduced from (45).  
1.4 Steroid metabolism in the prostate 
1.4.1 The classical and alternate 5α-dione pathways 
The circulating levels of T are almost completely diminished during ADT, declining to levels 
lower than 20 ng/dl (27). Under castrate conditions the prostate tumour is able to adapt and 
use adrenal androgen precursors to produce active androgens which can reactivate the AR 
axis. Initially, intratumoural biosynthesis of DHT using adrenal androgen precursors was 
thought to follow the conventional pathway whereby A4 (and DHEA which is converted to 
A4 by HSD3B2) is first converted to T by a 17-keto reduction catalysed by HSD17B5 
(AKR1C3), followed by the 5α-reduction of T by SRD5A1 to yield DHT. Recent studies 
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have, however, shown that the prevailing pathway for DHT biosynthesis in CRPC is the 
alternate 5α-dione pathway as illustrated in figure 1.5. In this pathway T production is 
bypassed completely and A4 is instead reduced by SRD5A, to produce 5α-dione which is in 
turn converted to DHT by AKR1C3 (46, 58, 59).  
 
Figure 1.5 5α-dione pathway illustrated by the green arrows circumvents T via 5α-reduction of A4 to form 5α-
dione, and subsequent HSD17B action to give rise to DHT in CRPC.  Reproduced from (58).  
Chang et al showed that A4 is the preferred substrate over T for SRD5A1, which is 
upregulated during CRPC (16, 59–62). Chang and colleagues (46) investigated androgen 
metabolism in six CRPC cell-lines and consistently found that the 5α-dione pathway was the 
dominant route to DHT production. This finding suggested that the pathway is common to the 
CRPC state. As ex vivo studies only provide a view of androgen concentrations limited to a 
moment in time (31, 63), Chang et al undertook further analyses of tumour biopsies from two 
patients and observed the same trends in these cells. The importance of the pathway in a 
clinical setting became evident, and the 5α-dione pathway was thus proposed by Chang et al 
to explain the increase observed in the T to DHT ratio seen in in CRPC tissue. Observations 
in untreated prostate cancer and BPH cells showed the T:DHT ratio to be approximately 1:10, 
which indicates a rapid flux from T to DHT. A general interpretation of these results was that 
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all DHT formed was from the conversion of T. However, clinical studies showed this ratio 
was reversed in CRPC. Chang et al, however, proposed that the reason for the increased ratio 
is that the flux to DHT formation does not readily occur through T but rather via the alternate 
pathway (46). This notion was supported by the increase in the T:DHT ratio observed in the 
prostates of normal men, when the flux from T to DHT is pharmacologically blocked (31, 63). 
A slight increase in T production would thus increase the T:DHT ratio as the conversion from 
T to DHT is not favoured. Furthermore, as AR agonists, it is important to note that androgen 
concentrations detected within the tumours in clinical studies disproportionately reflect 
androgens which are found in the interstitial space and cellular cytoplasm of the tumours (46). 
A more accurate representation of active androgens could be obtained by determining their 
internuclear concentrations as this would represent androgens bound to the AR (64). 
Ascertaining concentrations of DHT in the nucleus of clinical CRPC tissue have not yet been 
completed, but it is believed that DHT concentrations herein will exceed the sum of DHT in 
all other compartments of the tumour (31, 63).  
1.5 11OHA4 pathway 
In addition to A4, DHEA and DHEA-S the human adrenal gland also produces the C19 
steroid, 11OHA4 as discussed above. After being overlooked since its discovery over half a 
century ago, 11OHA4 has made a comeback as an adrenal precursor to active androgens 
which likely play a central role CRPC (65). The initial loss of interest in this metabolite was 
as a result of its weak androgenic activity and the production of the steroid was thought to be 
a mechanism by which adrenal androgens are inactivated (66). Recent studies have, however, 
revealed the potential physiological importance of 11OHA4.  
11OHA4 was shown to be the substrate for a novel pathway involving the enzymes HSD11B 
and SRD5A. The conversion of 11OHA4 to 11KA4 as well as the conversion of 11OHT to 
11KT, was shown to be catalysed via the action of HSD11B2 (11-hydroxy to 11-keto form) in 
LNcaP cells as shown in figure 1.6. HSD11B2, unlike HSD11B1 has been shown to be 
expressed in the prostate (67), further experiments need to be done to rule out HSD11B1 
fully. Both SRD5A1 and SRD5A2 were shown to be able to convert 11OHA4, 11KA4, 
11OHT and 11KT to the novel C19 steroids, 11OH-5α-dione, 11K-5α-dione, 11OHDHT and 
11KDHT, respectively. Although commercial standards are not available for these 5α-reduced 
steroids, their production was confirmed by accurate mass determinations (47). HSD11B2 
was shown to convert 11OH-5α-dione and 11OHDHT to 11K-5α-dione and 11KDHT, 
respectively. HSD17B3 and HSD17B5 were shown to catalyse the conversion of 11KA4 and 
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11K-5α-dione to 11KT and 11KDHT, respectively, while 11OHA4 and 11OH-5α-dione were 
not substrates for these enzymes. In addition, the reverse reactions were all catalysed by 
HSD17B2 (57, 65, 68). Taking the enzymes and reactions described above into account, the 
metabolism of 11OHA4 would result in the formation of 11KT and 11KDHT as shown in 
figure 1.6. Three potential metabolic routes from 11OHA4 to 11KDHT are, however, 
possible. The existence of the proposed 11OHA4 pathway was confirmed in the androgen 
dependent prostate cancer cell line, LNCaP (57). Furthermore, all the enzymes involved in the 
metabolism of 11OHA4 are expressed during CRPC (31, 67).  
Although 11OHA4 itself is not androgenic, the 11OHA4 pathway yields active androgens. 
11KT and 11OHDHT displayed partial AR agonist activity at the physiologically relevant 
concentration of 1 nM (11KT was comparable to T), while 11KDHT displayed full agonist 
activity, comparable to DHT (47, 57).  
 
Figure 1.6 C19 steroids on the 11OHA4 pathway. The enzymes responsible for the metabolism of 11OHA4 and 
downstream metabolites are HSD11B, HSD17B and SRD5A. The 5α-reduction of 11OHA4, 11OHT, 11KA4, 
and 11KT results in the production of novel C19 products 11OH-5α-dione, 11OHDHT, 11K-5α-dione and 
11KDHT, respectively. The pathway was confirmed in the androgen dependent prostate cancer line, LNCaP, 
which does not possess 11βHSD1 (47).  
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11OHA4 therefore clearly functions as a precursor to active androgens in the prostate, which 
contains the necessary enzymatic machinery. Furthermore, the identification of the 11OHA4 
pathway has revealed novel substrates for the enzymes involved in androgen metabolism. The 
metabolism of 11OHA4 and other C19 derivatives towards novel C19 steroids offers a robust 
mechanism which may not only have role in normal tissue which express the relevant 
enzymes but also in prostate diseases such as CRPC. Although numerous pathways have been 
identified for the metabolism of adrenal androgens within CRPC, it is likely that all the 
pathways make a contribution to the production of active androgens. The extent of the 
contribution will, however, depend on the availability of the adrenal androgen precursors as 
well as the preference of the specific enzymes for the different substrates. SRD5A1 
expression is upregulated during CRPC (69) and plays a vital role in the conventional, 5α-
dione and the 11OHA4 pathways. The aim of this study was therefore to characterise 
SRD5A1 towards all the potential substrates from the various pathways as to understand its 
substrate preference.  
1.6 Steroid 5α-reductase 
1.6.1 Background and history 
Three SRD5A isozymes have been identified to date and have been named based on the 
chronological order in which the cDNA was isolated (1). The reduction of T to DHT was first 
discovered in 1951, and was shown to be catalysed by the enzyme SRD5A. At the time 
researchers were unaware that multiple isozymes of the enzyme existed. Originally SRD5A 
was believed to play a role in the catabolism of steroids, by terminating endocrine hormone 
action. In 1968, however, DHT was shown to be a more potent androgen than T (3), 
demonstrating that SRD5A played an anabolic role (64). In 1974 the significance of SRD5A 
in human physiology was confirmed by the discovery of an inborn error of male sexual 
differentiation, due to a SRD5A deficiency. Males deficient in SRD5A exhibit developmental 
defects in the formation of external genitalia and prostate as a result of a defect in the 
biosynthesis of DHT in the embryo (16). The external genitalia resemble those of a female, 
while the internal genitalia (excluding the prostate) were normal. The observation that these 
men demonstrated incomplete prostate development along with decreased baldness and acne, 
served as the rational for the development of inhibitors for the enzyme, in treating these 
conditions in normal men. SRD5A was shown to have an acidic pH optimum in human 
prostate (70), epididymis or genital skin fibroblasts (71). SRD5A activity with an acidic pH 
optimum was absent in genital skin fibroblasts grown from subjects with SRD5A deficiency, 
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however, SRD5A activity with an alkaline pH optimum was identified, suggesting that 
multiple molecular forms of SRD5A may exist (72–74). Further investigations into the 
existence of multiple isoforms were hampered, as the enzyme proved to be highly insoluble 
(16), due to the SRD5A isozymes being integral membrane proteins located in the nucleus 
and endoplasmic reticulum (75, 76). Intrinsic membrane proteins are deeply embedded in the 
lipid bilayer, making these hydrophobic proteins very difficult to purify. After numerous 
attempts, solubility of the enzyme was achieved using detergents, but resulted in the loss of 
enzymatic activity upon purification (77–79). In 1989, the cDNA of full length rat SRD5A 
was cloned and expressed in Xenopus oocytes offering an alternative route to study enzyme 
function (80). This breakthrough allowed the cross-hybridisation screening of human prostate 
cDNA library for human SRD5A using expressed full length rat SRD5A as a hybridisation 
probe (81). cDNA encoding human SRD5A was successfully obtained using this method, and 
rat and human cDNA was subsequently expressed in simian COS cells. The cloned human 
enzyme (SRD5A1) was not sensitive to inhibition by the potent SRD5A inhibitor finasteride 
and demonstrated an alkaline pH optimum indicating that the cloned enzyme was not the 
same SRD5A first identified in tissue, again suggesting the presence of multiple isozymes. 
Furthermore, no mutations were found in the SRD5A cDNA from patients with SRD5A 
deficiency (73, 81). The cloned SRD5A was named SRD5A1. Male pseudohermaphroditism 
due to 5α-reductase deficiency was later shown to be due to a mutation in SRD5A2 (72, 82). 
Human cDNA SRD5A2 was later isolated by using an expression cloning method that 
isolated cDNA pools which displayed SRD5A activity different from the already isolated 
SRD5A1. Pools of active cDNA expressed in HEK-293 cells were gradually divided into 
smaller groups until SRD5A2 cDNA was isolated and confirmed by the expressed enzymes’ 
acidic pH optimum and sensitivity to finasteride (83). Normington and Russel subsequently 
isolated and characterised the cDNA encoding for rat SRD5A2 after they generated a probe 
for SRD5A2 cDNA using PCR (72). RNA isolated from the ventral prostates of castrated rats, 
treated with T for 3 days, was reverse transcribed to generate cDNA which was used as a 
template for subsequent PCR amplification. The amplified sequence produced an 
oligonucleotide probe that was used to identify a positive clone from a rat testes cDNA library 
(72).  
More recently a third SRD5A isozyme, SRD5A3, was discovered (84). SRD5A3 was 
originally identified in hormone refractory prostate cancer tissue via a genome-wide gene 
expression profile analysis of these cells (84). This isozyme has been shown to be 
overexpressed in CRPC, but the significance of this finding is yet to be fully elucidated (6). 
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Uemura and others have suggested that the third isoform of SRD5A might be responsible for 
the conversion of T to DHT in the presence of dutastide and finastride (84–86). Thus far, 
SRD5A3 has been shown to be mainly involved in polyprenol biosynthesis and it has been 
suggested that SRD5A3 does not play a significant role to play in intratumoral androgen 
biosynthesis (87). Cantegrel et al. showed, in both biochemical and clinical investigations, the 
proposed 5α-reductase domain of SRD5A3 reduces substrates which are not related to 
steroids but rather to nonsteroid lipids (87). In contrast, Titus et al. more recently showed that 
SRD5A3 is capable of 5α-reduction of 3-oxo-∆4,5 containing steroid substrates (85). 
1.6.2 Tissue distribution and regulation of SRD5A isozymes 
SRD5A1 is expressed in very low levels in embryonic tissues, while SRD5A2 is the 
predominant isozyme found in these tissues as is evident by the drastic phenotypic change 
observed in males with SRD5A2 deficiency. In a mature adult, SRD5A1 is highly expressed 
in nongenital skin, liver and certain brain regions, but it is expressed at significantly lower 
levels in the androgen-dependent tissue (prostate, epididymis, seminal vesicle and testis) as 
well as genital skin, adrenal glands and the kidney. In contrast, SRD5A2 has high expression 
in androgen-dependent regions, genital skin, adrenal glands, kidney, and is also, to a lesser 
degree, expressed in the ovaries and hair follicles (88, 89). Regulation of SRD5A expression 
is achieved in prostate and liver tissue by hormonal control with androgen induced expression 
of SRD5A seemingly mediated by IGF-1 which is expressed at high levels in the prostate 
(82).  
1.6.3 Characterisation of SRD5A 
SRD5A1 exhibits a broad pH optimum, which ranges between 6.0 and 8.5, while SRD5A2 
exhibits a narrow acidic pH optimum (pH 5– 5.5) in the lysates of transfected cells (3, 16). 
SRD5A2 has been observed to have a higher Vmax/Km ratio than SRD5A1 when compared 
under optimal conditions suggesting a higher 5α-reducing activity (3). Both isozymes contain 
an NH2-terminal ligand binding domain and a COOH-terminal NADPH binding domain. Both 
SRD5A1 and SRD5A2 have similar apparent dissociation constants for NADPH (3–10 µM) 
(3, 61). The apparent dissociation constant of NADPH for SRD5A3 is undetermined. Azzouni 
and colleagues have shown that SRD5A2 has a pH optimum between pH 6.0 and 7.0 inside 
intact human cells (3). Lysates of CHO cells expressing SRD5A1 from rat and human, 
produces an enzyme with micromolar affinity (apparent Km = 1-5 µM) for substrates such as 
T, A4, and progesterone (81). However, under optimal conditions (pH 5.0) the apparent Km of 
SRD5A2 for T is in the submicromolar range (0.1-1.0 µM) with a Vmax of 2.0-5.0 nmol of 
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DHT per mg protein (90). Interestingly, under sub-optimal conditions (pH 7.0) the apparent 
Km values obtained for SRD5A2 in cell lysates, permeabilized cells, and intact cells are in the 
low nanomolar range (4-50 nM), while the Vmax is reduced to 0.2 nmol DHT per mg protein 
(61). Based on Vmax/Km versus pH plots, the most efficient range for SRD5A2 activity was 
determined to be between pH 6.0 and 7.0 (61). 
Table 1.2 Comparison of properties of 5α-reductase isoenzymes relevant in CRPC (91) 
Properties SRD5A1 SRD5A2 
Biochemical state Hydrophobic Hydrophobic 
Chromosome location 5p15 2p23 
Molecular weight (kDa) 29.5 28.4 
Optimal pH 6-8.5 5-5.5 
Size 259 amino acids 254 amino acids 
Tissue distribution Liver, nongenital skin, 
prostate, brain, ovary, testis 
prostate, epididymis, 
seminal vesicle, 
genital skin, uterus, breast, 
hair follicle, placenta, testis 
 
Characterisation of the native enzyme has proved to be cumbersome since, as mentioned 
above, the SRD5A isozymes are membrane-bound proteins, embedded in the membrane bi-
layer of the ER. In addition the overall topology of these hydrophobic proteins have not been 
determined, with an earlier study, using differential permeablization of transfected CHO cell 
membranes, showing that the carboxyl termini of the 5α-reductase isozymes lie on the 
cytoplasmic side of the endoplasmic reticulum bilayer. (80). In a previous study in the mid-
1980s, solubilisation of active human prostatic SRD5A was successfully achieved from 
microsomal pellets, in order to facilitate further purification and characterisation (77). Even 
after several attempts by many laboratories SRD5A is yet to be purified in an active form (16, 
74, 78, 79, 91). Detergents are required to solubilize the proteins, which leads to the loss of 
function of the unstable enzyme upon chromatographic purification steps (77). In addition, 
SDS-PAGE analysis of purified proteins have shown that the isozymes exhibit an 
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uncharacteristic electrophoretic mobilities (16, 61, 92), as the proteins migrate at apparent 
molecular masses of 21,000-27,000 instead of the predicted 28,000- 29,000.  
The substrates for SRD5A1 and SRD5A2 are 3-oxo ∆4-5 C19/C21 steroids. The 3-oxo refers to 
the oxygen moiety (keto group) at C3 and ∆4-5 refers to the double bond between C4 and C5. 
SRD5As catalyse an irreversible, stereo-specific double bond breakage, while inserting a 
hydride anion to the α face at C5 and a proton to the β face at C4 (figure 1.7) (3, 93). 
 
Figure 1.7 Proposed mechanism for reduction of T by SRD5A. Reproduced from (94).  
In the catalytic reaction, NADPH is the first to bind the enzyme and NADP
+
 is the last 
product to leave the enzyme, thus the reaction has an ordered bi-bi kinetic mechanism as 
illustrated in figure 1.8. NADPH provides the hydride ion for C5 and a proton (from water) 
attaches to C4. There is no direct transfer of hydrogen from NADPH to the ∆4-5 double bond 
in the 3-oxosteroid. Unlike most reactions involving NADPH which are freely reversible, the 
5α-reductase catalysed reaction is irreversible (93) with the resultant 5α-reduction of the 
steroid causing the molecule to have a planar structure and to be less polar due to the 
rearrangement of the A and B rings. The 3-oxo groups of 5α-reduced products are more easily 
reduced by 3α/3β hydroxysteroid dehydrogenase, sulfation and glucuronidation. The 
modification of 5α-reduced products facilitates excretion, by rendering these steroids more 
hydrophilic (16).  
 
Figure 1.8 Ordered bi-bi reaction scheme for SRD5A. Modified from (94). 
1.6.4 Pharmacology of SRD5A 
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The 5α-reduction of C19 steroids such as T and 11KT leads to the production of active 
androgens capable of activating the AR. The physiological importance of SRD5A2 is clearly 
demonstrated by the inactivating SRD5A2 mutation which resulted in male 
pseudohermaphroditism and prevented the development of the prostate gland as discussed 
above. This observation, together with high levels of SRD5A2 expression detected in normal 
prostatic tissue as well as the observation that SRD5A2 has a higher affinity towards T than 
SRD5A1, led to the initial view that SRD5A2 was the only SRD5A isoenzyme with clinical 
relevance in the prostate (6). Finasteride was therefore developed for the prevention and 
treatment of prostate cancer. Finasteride is a potent 4-azasteroid inhibitor of human SRD5A2 
which is much less effective at inhibiting human SRD5A1 (61). Finasteride treatment, 
however, failed to reduce intraprostatic DHT to the desired levels. Dutastride was later 
developed due to the inability of finastride to effectively inhibit DHT production. Dutasteride 
inhibits both SRD5A1 and SRD5A2, and is more potent than finastride (95). A greater 
reduction in serum and intraprostatic DHT levels was observed when using dutastride, 
confirming the suggestion that SRD5A1 may contribute more significantly to prostatic DHT 
formation than initially thought. More recent studies have confirmed that SRD5A1 is 
associated with the development and progression of prostate cancer. SRD5A1 mRNA 
expression levels are significantly higher in prostate cancer than the levels detected in BPH 
and normal prostate tissue (96). A growing body of evidence suggests that when a decrease in 
SRD5A2 activity, with a simultaneous rise in SRD5A1 mRNA expression is observed, it 
leads to the development of primary prostate cancer. This change in the ratio of  SRD5A1 and 
SRD5A2 expression levels is also observed in CRPC (69, 97, 98). Clinical trials with 
dutastide and finastride resulted in a short remission period followed by the development of a 
more aggressive form of cancer in a subset of patients. For this reason dutastide and finastride 
are not approved by the Food and Drug Administration (FDA) for the prevention of prostate 
cancer (99). This decision was based on the inhibition of SRD5A resulting in the 
accumulation of T or other DHT precursors which are able to activate the wild type and 
mutated AR.  
1.6.5 Characterisation of SRD5A1 towards novel substrates 
The peripheral metabolism of A4, DHEA and 11OHA4 have been shown to yield androgenic 
products, while these steroids themselves are not significantly androgenic (17–19). The role 
played by SRD5A1 in the metabolism of these adrenal androgen precursors is clear. However, 
the enzymatic activity of SRD5A1 towards the novel substrates identified in the newly 
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discovered 11OHA4 pathway is yet to be determined. It is therefore the aim of this study to 
characterise SRD5A1 activity towards 11OHA4, 11KA4, 11OHT and 11KT and to compare 
these activities to the known substrates, A4 and T. These results will firstly allow us to better 
understand the flux through the 11OHA4 pathway and secondly, will provide insight into 
which of the adrenal androgen precursors are the preferred substrates for intratumoral 
androgen synthesis. Two approaches for the characterisation of SRD5A1 were followed 
during this study: (1) SRD5A1 was expressed in HEK293 cells, a human embryonic kidney 
cell line, as to assess the enzymatic activity of SRD5A1 in a nonsteroidogenic mammalian 
cell model; (2) SRD5A1 was expressed in a yeast expression system in order to produce high 
levels of enzyme which could be used for the biocatalytic production of the novel 5α-reduced 
products, 11OH-5α-dione, 11K-5α-dione and 11OHDHT (which are currently not available 
commercially) as well as 11KDHT. 
1.7 Expression of SRD5A1 in HEK-293 cells 
Characterisation of enzymes expressed in different systems each come with their own set of 
pros and cons. Recombinant strategies to overcome difficulties in purifying these integral 
membrane proteins from natural sources, have been implemented to express SRD5A in a 
number of expression systems (80, 81). These systems include, amongst others, Xenopus 
oocytes (80), Saccharomyces cerevisiae (100), insect cells (Spodoptera frugiperda) (101) and 
mammalian cell lines such as Green Monkey kidney (COS-1) cells (81), Chinese hamster 
ovary (CHO) (61)  and HEK-293 cells  (72, 83, 86, 90, 102, 103). As most of what is known 
about SRD5A surfaced as a result of heterologous expression of the enzyme, the 
characterisation of SRD5A1 towards novel C19 substrates by these methods would be a 
natural choice. In mammalian cell lines proper folding, post-translational modifications and 
product assembly is achieved easily and can thus facilitate the characterisation of an enzyme. 
Numerous research groups have utilised HEK-293 to express SRD5A successfully and to 
complete kinetic characterisation of the enzyme in the presence of novel drugs and substrates 
(57, 86, 102–104). The enzymatic activity of SRD5A1 towards 11OHA4, 11KA4, 11OHT 
and 11KT has, however, not been characterised. It is well documented that SRD5A1 has a 
higher affinity for A4 over T (105) and preliminary data has suggested that the same is true 
for the 11β-hydroxyl and 11-keto derivatives of A4 and T (47). The characterisation of 
SRD5A1 towards 11OHA4 11KA4, 11OHT and 11KT will elucidate the preferred flux 
through the 11OHA4 pathway and will allow for a better understanding of intratumoral 
androgen metabolism.   
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1.8 Expression of SRD5A1 in P. pastoris 
The functional expression of rat and human SRD5A has been achieved in a number of 
eukaryotic systems as listed above, however, these systems are generally regarded as complex 
and costly systems (61, 80, 81). Yeast expression systems, on the other hand, are cost 
effective with the added benefit of high levels of expression (106). Yeast can be transformed 
with plasmids containing the gene of interest and subsequent recombination leads to the 
incorporation of multiple copies of the gene of interest into the yeast genome facilitating 
overexpression of the encoded protein (107). Yeast expression systems are regarded as 
invaluable biotechnology for studying the structure and function of proteins, in particular, 
membrane bound proteins as well as proteins that are expressed in low levels in tissue (100, 
108). Numerous studies have shown the ability of yeast to achieve post-translational 
modifications required for the activity of proteins involved in steroid metabolism (75, 100, 
109). Ordman et al. previously demonstrated the expression of catalytically active rat SRD5A 
in S. cerevisiae (75). T was efficiently converted to DHT confirming functional expression 
and uptake of hydrophobic steroid substrates. SRD5A activity was maintained even when 
intact yeast, spheroplasts, or lysed yeast were snap frozen and stored at -20 or -70°C (9).  
Interestingly, a second reaction product was observed during prolonged incubation periods 
with T. TLC analysis revealed that the product co-migrated with 5α-androstan-3α-17β-diol 
(3α-adiol) and 5α-andorstan-3β-17β-diol (3β-adiol), suggesting that yeast may express a 3α- 
or 3β-hydroxysteroid dehydrogenase activity which can metabolise DHT (75). The study 
showed that yeast not expressing SRD5A (negative control) were unable to metabolise T, 
while being able to metabolise DHT due to the endogenous 3α- or 3β-hydroxysteroid 
dehydrogenase activity (75, 100). Our laboratory has investigated the use of S. cerevisiae for 
the expression of CYP17A1, however, desired yields were not achieved. The yeast Pichia 
pastoris (also known as Komagatella pastoris (110)), however, was shown to yield desired 
protein expression levels (109). Hult et al. also previously demonstrated the successful 
expression of the steroid metabolising enzyme HSD11B1 in P. pastoris. During this study, the 
authors determined the substrate specificities and inhibitor constants for synthetic and 
naturally occurring compounds and demonstrated that recombinant human HSD11B1 
expressed in P. pastoris behaves as it does in mammalian systems (111).  
The P. pastoris yeast system has become one of the most popular heterologous protein 
expression systems since 1993 when it was released by the Phillips Petroleum Company for 
academic research laboratories to utilise freely (106, 112). P. pastoris is a methalotrophic 
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yeast – as utilises methanol as its sole carbon source for energy. An added benefit to using P. 
pastoris as a protein expression system is the yeast’s ability to withstand relatively high levels 
of methanol in which most other micro-organisms could not survive (106). P. pastoris has the 
ability to produce high cell densities in relation to fermentative yeasts due to its strong 
preference for respiratory growth (113). Cell growth is often accompanied by the production 
of high levels of functional proteins, which include membrane-bound proteins. Heterologous 
genes can be integrated into the yeast genome downstream of an alcohol oxidase 1 promoter 
(AOX1p), resulting in the tightly regulated, methanol-induced expression of recombinant 
proteins (114).  
The molecular genetic manipulations required for the integration of a heterologous gene into 
the genome of P. pastoris are similar to those required for one of the most well characterised 
experimental system in modern biology, S. cerevisiae. An integrative vector, pPIC3.5K, is 
used to facilitate the stable integration of exogenous DNA into the host genome. Single or 
multiple copy numbers can be stably integrated into the yeast genome even in the absence of 
selective pressure (106). The pPIC3.5K vector (figure 4.1) is designed to enable multiple 
integrations of the gene of interest into the genome of P. pastoris. Multicopy candidate strains 
are screened by first selecting for a HIS+ phenotype and subsequently replating positive 
transformants on YPD-agar plates containing increasing concentrations of G418 (Geneticin) 
(115).  
 
Figure 1.9 Map of yeast expression plasmid pPIC3.5K. P. pastoris AOX1 gene promoter, 5ʹAOX1; AOX1 
transcription terminator, 3ʹ AOX1 (TT); Histidinol dehydrogenase gene, HIS4; 3ʹ AOX1downstream sequence, 
3ʹ AOX1; Ampicillin resistance gene, Ampicillin; Kanamycin resistance gene, Kanamycin; pBR322, E. coli 
origin of replication (116).  
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P. pastoris was the system of choice for investigating the heterologous expression of 
SRD5A1 due to the success achieved in our laboratory with the stable transformation and 
subsequent expression of the membrane bound steroidogenic enzyme CYP17A1 in this yeast 
(109). The aim of this trial was to determine if functional expression of human SRD5A1 
could be achieved in P. pastoris with the end goal of using the system to produce 11OH-5α-
dione, 11K-5α-dione, 11OHDHT and 11KDHT. 
1.9 Objectives 
Prostate cancer is a prevalent disease which often develops into CRPC which is fatal. Recent 
studies, outlined above, have shown that CRPC is dependent on a number of steroid pathways 
which convert adrenal androgen precursors into potent androgens. The characterisation of 
these pathways and enzymes therein is therefore vital to understand the progression of this 
disease and for the identification of the most suitable drug targets.  
The objective of the present investigation was therefore to characterise the activity of 
SRD5A1 towards the novel C19 substrates in the recently identified 11OHA4 pathway. 
Specific aims were: 
 To characterise SRD5A1 expressed in HEK293 cells towards A4, T, 11OHA4, 
11KA4, 11OHT and 11KT. 
 To determine if functional expression of SRD5A1 is possible in P. pastoris. 
 To determine if the yeast model could be used as a biocatalyst for the production of 
C19 androgens which are not available commercially.  
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Chapter 2 
MATERIALS AND METHODS 
2.1 Plasmids  
The pCMV7 vector containing human SRD5A1 was obtained from Prof. DW Russel 
(Southwestern Medical School, University of Texas, Dallas, USA). The pCIneo and 
pPIC3.5K plasmids were available for use in the laboratory. 
2.2 Reagents  
HEK-293 cells were purchased from the American Type Culture Collection (Manassas, VA, 
USA). Penicillin-streptomycin, fetal calf serum and trypsin-EDTA were obtained from Gibco-
BRL (Gaithersburg, MD, USA). 11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-
hydroxytestosterone and 11-ketotestosterone were purchased from Steraloids (Wilton, USA). 
Testosterone, androstenedione, 5α-androstenedione, dihydrotestosterone, as well as Geneticin 
disulphate (G418), Lyticase and Dulbecco’s modified Eagle’s medium was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Deuterated cortisol (9, 11, 12, 12- D4-cortisol) and 
deuterated testosterone (D2-T) were purchased from Cambridge isotopes (Andover, MA, 
USA). Nuclease free water was purchased from Ambion, Applied Biosystems (Austin, Texas, 
USA). Restriction endonucleases (EcoRI, PstI, SalI and NcoI), Pfu polymerase as well as the 
1kb DNA marker were purchased from Fermentas (Burlington, Canada). X-tremeGENE HP 
DNA transfection reagent and Rapid DNA dephos and ligation kit was from Roche 
Diagnostics (Mannheim, Germany). Wizard® SV Gel Clean-Up and Zyppy® Plasmid 
miniprep Kit were purchased from Promega Biotech (Madison, WI, USA) and Inqaba Biotec 
(Pretoria, RSA), respectively.  P. pastoris strain GS115 (his4) was purchased from Invitrogen 
(Carlsbad, CA, USA). Nucleobond® Midiprep DNA isolation kits were purchased from 
Macherey-Nagel (Duren, Germany). All yeast growth media components were purchased 
from Difco Laboratories (Detroit, MI, USA) and Zymolase
TM
 was purchased from Zymo 
Research Corporation (Irvine, CA, USA). All other chemicals were of the highest analytical 
grade and purchased from scientific supply houses. All protocols were carried out according 
to the manufacturer’s instructions unless otherwise stated.  
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2.3 pCMV7-SRD5A1, pPIC3.5k and pCIneo plasmid preparation 
Luria-Bertani (LB) medium, 100 ml, containing ampicillin, 100 µg/ml, was inoculated with 
E.coli strain JM109 containing either pCMV7-SRD5A1, pCIneo or pPIC3.5k and incubated 
overnight at 37°C while shaking at 200 rpm (Innova shaking incubator, New Brunswick). 
Plasmid DNA was isolated using a Nucleobond® Midiprep DNA isolation kit. The resulting 
plasmid DNA pellets were resuspended in 600 µl nuclease free water. Plasmid DNA 
concentration and yield was determined spectrophotometrically using a Cary 60 UV-VIS 
(Agilent technologies). Plasmids were subsequently analysed by restriction endonuclease 
digestions. The total reaction volume was 20 µl and each reaction contained: the appropriate 
enzyme BSA-buffer (10X), 2 µl; EcoRI (10 U/µl), 5U, 0.5 µl; and 1 µg plasmid DNA. 
Reactions were incubated at 37°C for 1 hour. Digested and undigested plasmids were 
subsequently analysed by 1% agarose gel electrophoresis using a 1kb DNA marker. The DNA 
samples (0.5 µg) were diluted in 0.2% loading buffer (0.1% Orange G (w/v), 20% Ficoll 
(w/v), 10 mM EDTA). Electrophoresis was carried out at room temperature in TAE buffer (40 
mM Tris-acetate, 2 mM EDTA and 20 mM acetic acid) at 110V for three minutes and at 75V 
until the dye front was 1 cm from the bottom of the gel. The agarose gel was stained using GR 
green® prior to visualisation on a UV transluminator. 
2.4 SRD5A1 expression in HEK-293 cells 
2.4.1 Cell culture procedure 
HEK-293 cells were routinely grown to confluence in 75 cm
3
 culture dishes at 37ºC, 90% 
humidity and 5% CO2 in DMEM, supplemented with 0.12% NaHCO3, 10% fetal calf serum 
and 1% penicillin–streptomycin (stock containing 10 000 U/ml penicillin and 10 000 μg/ml 
streptomycin). Cell count and viability were determined using trypan blue and Countess® 
Automated cell counter (Invitrogen).  
2.4.2 Enzymatic assays in transiently transfected HEK-293 cells 
HEK-293 cells were grown to confluence and cells were plated into 24-well culture dishes 
with each well containing 2×105 cells (500 µl/well) 24 hours prior to transfection. Cells were 
transiently transfected using X-tremeGENE HP DNA transfection reagent using a 3:1 ratio of 
transfection reagent (µl) to plasmid DNA (µg) in serum-free medium (DMEM without FSB 
supplementation). After 15 minutes at room temperature, 50 µl of the transfection cocktail 
was added to each well in a drop-wise manner and the cells were incubated for a further 72 
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hours prior to substrate addition. The media was replaced with media supplemented with 
either 11OHA4, 11KA4, 11OHT, 11KT, A4 or T at a final concentration of 0.5, 5 or 30µM. T 
(5 µM) was included in all experiments as a positive control for enzyme expression. Aliquots, 
500 µl, were collected at specific time intervals: all steroids were assayed at 0.5 µM, aliquoted 
at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4 and 6 hours; 11OHA4 and 11KA4 were assayed at 5 μM, 
aliquoted at 0, 0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours; 11OHT and 11KT were assayed at 5 μM, 
aliquoted at 0, 2, 4, 6, 10, 12, 14, 18 and 24 hours; A4 and T assayed at 5 μM aliquoted at 0, 
0.5, 1, 1.5, 2, 3, 5, 7 and 10 hours; all steroids were assayed at 30 µM, aliquoted at 0, 1, 2, 3 
and 4 hours. Samples were stored at 4°C prior to extraction and UPLC-MS/MS analysis.  
2.5 Steroid extraction  
Steroids were extracted from aliquotes by liquid-liquid extraction using a 10:1 volume of 
dichloromethane to sample collected. D4-cortisol (15 ng) and D2-T (15 ng) were added to the 
samples prior to extraction, after which the samples were vortexed for 15 minutes and 
centrifuged at 3500 rpm for 5 minutes at room temperature. The polar phase was aspirated 
and the non-polar dichloromethane phase transferred to a clean test tube and evaporated under 
a stream of nitrogen gas (N2). The dried steroids were reconstituted in methanol, 150 µl, prior 
to analysis by UPLC-MS/MS. Sample from the experiments containing 30 µM steroid were 
diluted 10x in methanol prior to analysis by UPLC-MS/MS.  
2.6 UPLC-MS/MS analysis of steroids 
Steroid metabolites were separated by UPLC (ACQUITY UPLC, Waters, Milford, USA) 
using a Phenomenex Kinetex PFP (2.1 mm × 100 mm, 2.6 µm) column as previously 
described (47, 57). The mobile phases consisted of solvent A (1% formic acid) and solvent B 
(49:49:2, methanol:acetonitrile:isopropanol) (44). The gradients used for separation are 
shown in table 2.1. The total run time was 5 minutes and the injection volume was 5 µl. A 
Xevo triple quadrupole mass spectrometer (Waters, Milford, USA) was used for quantitative 
mass spectrometric detection. All steroids were analysed in multiple reaction monitoring 
(MRM) mode (table 2.2) using an electrospray probe in the positive ionization mode (ESI+). 
The following settings were used: capillary voltage of 3.5 kV, source temperature 120°C, 
desolvation temperature 400°C, desolvation gas 900 l h−1 and cone gas 50 l h−1. Data was 
collected with the MassLynx 4.1 software. Standard curves were generated for each steroid 
metabolite using the following concentrations: 0.05, 0.5, 2.5 and 5.0ng/ml. The calibration 
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curves were linear over these concentration ranges, with regression correlation coefficients 
(r
2
) always being greater than 0.99.  
Table 2.1 UPLC gradient specifications of the chromatographic separation of the C19 steroids  (57).  
Step Time (minutes) % Solvent A % Solvent B Curve 
1 0.00 85.0 15.0 6 
2 1.00 60.0 40.0 6 
3 3.50 45.0 55.0 6 
4 3.60 0.0 100.0 6 
5 4.00 0.0 100.0 6 
6 4.01 85.0 15.0 6 
7 5.00 85.0 15.0 6 
 
Table 2.2 Parameters for the detection and quantification of C19 steroids by UPLC–MS/MS: retention times 
(RT); cone voltages (CV); collision energy (CE); limit of detection (LOD) (defined as a S/N >3); limit of 
quantification (LOQ) (defined as a S/N >10); and regression correlation coefficient (r
2
) (57).  
Steroid 
metabolite 
RT 
(minutes) 
Parent 
ion 
CV Daughter 
ion A 
CE Daughter 
ion B 
CE LOD 
(ng/ml) 
LOQ 
(ng/ml) 
r2 
11KT 2.24 303.2 30 121.0 20 267.0 20 0.7 2 0.99 
11OHT 2.25 305.3 35 121.0 20 269.0 15 0.07 0.2 0.99 
11OHA4 2.36 303.2 30 121.0 30 267.0 15 0.07 0.2 0.99 
11KA4 2.46 301.2 35 241.0 30 257.0 25 0.2 0.4 0.99 
T 3.07 289.2 30 97.2 22 109.0 22 0.07 0.2 0.99 
A4 3.23 287.2 30 96.9 15 108.8 15 0.07 0.2 0.99 
 
2.7 Determination of response factors  
Standards for UPLC-MS/MS analysis of the novel steroids, 11OH-5α-dione, 11K-5α-dione, 
11OHDHT and 11KDHT were not commercially available and these metabolites were 
Stellenbosch University  https://scholar.sun.ac.za
 
 
27 
therefore quantified by generating standard curves integrating data of their respective 
substrates. The peak areas of the 5α-reduced products were adjusted using response factors. 
Response factors were determined as follows: HEK-293 cells were plated as described above 
and co-transfected with SRD5A1 (0.5 µg) and SRD5A2 (0.5 µg) using the X-tremeGENE HP 
DNA transfection reagent. Control transfections were carried out using the mammalian 
expression vector pCIneo (1.0 μg) (no cDNA inserted). After a 72 hour incubation period, 
1 µM of steroid substrate (T, A4, 11OHA4, 11OHT, 11KA4 and 11KT) was added to cells 
expressing SRD5A1-SRD5A2 and pCIneo transfected HEK-293 cells after which the cells 
were incubated for 48 hours. Samples were collected and the steroids extracted and analysed 
as described above. D4-cortisol (15 ng) and D2-T (15 ng) were added to the samples prior to 
extraction. The peak areas of the substrates and their respective 5α-reduced products were 
determined after ascertaining that SRD5A samples contained only 5α-reduced steroids (no 
substrate remaining) and pCIneo samples contained only substrate precursor. The assumption 
was therefore made that the substrate was fully converted to the respective 5α-reduced 
product (1 μM substrate = 1 μM product). Response factors were determined using the 
formula below: 
  
   
    
  
   
  
Where: AS = peak area of the substrate; AIS = peak area of the internal standard; AP = peak 
area of the 5α-reduced product; [S] = substrate concentration; [P] = product concentration.  
The peak areas of each sample were divided by the area of the internal standard for each of 6 
replicates. The average ratio of substrate steroid/internal standard was divided by the average 
ratio of 5α-reduced product/internal standard in order to obtain the response factor.  
2.8 Determination of kinetic parameters 
Kinetic parameters (Vmax and Km) were determined using progress curve analysis. The 
following objective function was minimised in Mathamatica (Wolfram) for the respective 
substrates (S), in order to estimate the Vmax and Km values of SRD5A1: 
∑(
             
      
)
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E represents the experimental values and M the model predicted values for S. The Michaelis-
Menten equation was used as a model for the predicted change in S. The equation was 
numerically integrated to calculate S during the conversion. Data obtained from different 
experiments with different transfection efficiencies was normalised by using a control 
conversion of 5 μM T which was included in each experiment. All kinetic parameter 
determinations (from the experimental data) were carried out by Prof JL Snoep (Department 
of Biochemistry, University of Stellenbosch).  
2.9 Subcloning of SRD5A1 into the pPIC3.5K expression vector 
2.9.1 Amplification of SRD5A1 cDNA 
The pCMV7-SRD5A1 construct, was used as the template for the amplification of the 
SRD5A1 cDNA sequence. Primers were designed to include a Kozak consensus sequence in 
the upstream primer (for correct initiation of translation of gene of interest) as well as to 
include EcoRI recognition sites on the 3’ and 5’ termini of the cDNA sequence as shown in 
table 2.1. 
Table 2.3 SRD5A1 and AOX1 primer sequences used in sub-cloning, direct DNA sequencing and screening. 
The first primer pair (SRD5A1) is complementary to the 5ʹ and 3ʹ ends of the SRD5A1 coding sequence. EcoRI 
recognition sites are shown in bold and the Kozak consensus sequence is underlined. The second primer pair 
(AOX1) is complementary to the 5ʹ and 3ʹ ends of AOX1 gene, used to identify the incorporation of the gene of 
interest into genome of P. pastoris. 
Primer Oligonucleotide sequence 
SRD5A1 (Sense) 5'-GTATCGAATTCGCCACCATGGCAACGGCGACGGGGGTGGCG-3' 
SRD5A1 (Antisence) 5'-CGTAGCGAATTCTTAAAACAAAAATGGAATTATAATTTT-3' 
AOX1 (Sense) 5'-GACTGGTTCCAATTGACAAGC-3' 
AOX1 (Antisence) 5'-GCAAATGGCATTCTGACATCC-3' 
 
PCR was carried out using a PCR-Sprint thermo cycler (Hybraid). Each PCR amplification 
mixture (50 µl) contained: the appropriate reaction buffer containing MgSO4 (10X), 5 µl, 20 
mM MgSO4; 200 µM of each dNTP; 0.6 µM of each primer; 2.5 U Pfu-polymerase; and 
pCMV7-SRD5A1 plasmid DNA (750 ng). The amplification profile was as follows: (1) 
denaturing of the template at 95°C for 2 minutes; (2) 35 cycles of denaturing at 95°C for 30 
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seconds, annealing at 47.5°C for 30 seconds and extension at 72°C for 2 minutes; (3) and a 
final extension at 72°C for 10 minutes. The resulting amplicons were analysed on a 1% 
agarose gel. Four PCR amplifications were performed for the amplification of SRD5A1 
cDNA and then pooled prior to cloning.  
2.9.2 Cloning of SRD5A1 into the pPIC3.5K vector 
SRD5A1 cDNA was purified using a Wizard® SV Gel Clean-Up kit following amplification 
by PCR. The concentration of the purified cDNA was determined spectrophotometrically at 
260 nm. The cDNA, 1 µg, was subsequently digested with EcoRI, 10U, at 37°C for 90 
minutes.  
The pPIC3.5K vector was prepared for cloning as follows: The vector, 1 µg, was linearized by 
an EcoRI, 10 U, digest for 90 minutes at 37°C. The linearized vector, 0.75 µg, was 
dephosphorylated using 1 U of the rAPid Alkaline Phosphatase in a final volume of 20 µl by 
incubating at 37°C for 10 minutes. The enzyme was subsequently inactivated at 75°C for 2 
minutes. The prepared vector and cDNA were ligated using the Rapid DNA 
Dephosphorylation and Ligation Kit with a 1:5 molar ratio of vector: insert DNA. Ligation 
reactions, 10μl, contained: reaction buffer (20X), 0.5 µl; 50 ng DNA insert; 100 ng of vector; 
and 1.5 U of T4 ligase. The following control reactions were included: dephosphylated 
plasmid DNA (100 ng) without insert (negative control); and linearized plasmid DNA (100 
ng) which had not been dephosphorylated (dephosphorylation control). Competent DH5α 
cells were subsequently transformed with the ligated vectors. 
2.9.3 Transformation of E. coli strain DH5α with pPIC3.5K-SRD5A1  
Competent cells were prepared using the CAPS method (Modified Inoue method) (117), 
stored at -80°C and thawed when needed. E. coli strain DH5α cells were streaked on a LB-
agar plate and incubated overnight at 37°C. A single colony was picked and grown overnight 
in 5 ml of LB medium at 37°C shaking at 200 rpm. Fresh LB medium, 200 ml, was inoculated 
with overnight culture, 1.5 ml, and grown for a further 3 hours to OD600 of 0.5. The cells were 
subsequently centrifuged at 3000 rpm for 15 minutes at 4°C. DH5α cells were resuspended in 
16 ml ice-cold CAPS buffer (60 mM CaCl2, 15% glycerol and 10 mM PIPES). Hereafter, 
cells were again centrifuged in pre-cooled centrifuge tubes at 3000 rpm for 15 minutes at 4°C. 
The supernatant was discarded and the pellet resuspended in 4 ml ice-cold CAPS buffer. 
Aliquots, 200 µl, were prepared in microcentrifuge tubes and stored at -80°C until use.  
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Competent DH5α cells were thawed on ice for 25 minutes prior to transformation. Each 
ligation reaction, 20 µl, as added to 200 µl of competent cells, gently mixed and incubated on 
ice for 30 minutes. Transformation reactions included; dephosphorylated vector with insert; 
dephosphorylated vector with no insert (negative control); linearized plasmid DNA which had 
not been dephosphorylate (dephosphorylation control); and 5 ng of PUC19 (positive control). 
The cells were subsequently subjected to heatshock at 42°C for 45 seconds followed by 
incubation at room temperature for 2 minutes. Super optimal broth with catabolite repression 
medium (SOC) (2% w/v tryptone, 0.5% w/v Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2 and 20 mM Glucose; pH7.0), 800 µl, was subsequently added and the cell 
suspension incubated for 1 hour at 37°C shaking at 200 rpm. Dilutions of the transformation 
reactions were plated on LB-agar plates supplemented with ampicillin (100 µg/ml) and 
incubated overnight at 37°C.  
Single colonies were selected from the plates and used to inoculate 5 mL LB supplemented 
with ampicillin (100 µg/ml). Cultures were grown overnight at 37°C, shaking at 200 rpm. 
Plasmid DNA was isolated from the overnight cultures using the Zyppy® Plasmid Miniprep 
Kit. Potential SRD5A1 clones were digested with NcoI (10 U) in order to identify plasmids 
containing SRD5A1 cDNA as well as to determine the orientation of the insert. Digests were 
analysed on a 1% agarose gel. Plasmids containing the correct orientation of cDNA insert 
were subsequently subjected to direct sequence analysis at the Central Analytical Facility 
(CAF) of Stellenbosch University using the SRD5A1 forward and reverse primers listed in 
Table 2.1.  
2.10 Transformation in GS115 strain of P. pastoris  
2.10.1 Maintenance of P. pastoris 
Routine growth of P. pastoris strain GS115 was carried out in YPD medium (1% Yeast 
extract, 2% peptone and 2% D-glucose) shaking at 275 rpm at 30°C. All cultures were started 
from a single colony which was incubated on YPD-agar (YPD medium with 15 g agar per 
litre) for 2 days prior to inoculation. Selection of yeast transformants was carried out on 
minimal dextrose plates (MD) containing 13.4 g yeast nitrogen base without amino acids, 
400 µg biotin, 5 ml methanol and 15 g agar per litre and subsequently on YPD-agar  
containing increasing concentrations (0.25, 0.5, 0.75, 1.0 mg/ml) of Geneticin® (G418). 
Heterologous expression P. pastoris was achieved by culturing in buffered minimal glycerol 
(BMGY) medium (0.1 M potassium phosphate pH 6.0, 1.34% w/v YNB w/o amino acids, 
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0.00004% biotin, 1% v/v glycerol) for at least 24 hours and induced in buffered minimal 
methanol (BMMY) medium containing 0.5% v/v methanol replacing 1% v/v glycerol in 
BMGY medium.  
2.10.2 Transformation 
The cell wall of yeast hinders the uptake of DNA and it is thus necessary to either partially 
remove the cell wall or to create pores in order to allow transformation to occur. 
Transformation is less efficient in P. pastoris than in S. cereversiae (116, 118). 
Spheroplasting and electroporation have been documented to yield the highest transformation 
efficiency (±104 transformants per µg DNA) (116, 118). A method combining PEG and LiCl 
has been shown to yield lower transformation efficiencies (± 103 transformants per µg DNA), 
but is less laborious, uses intact cells and requires no specialized equipment (118). 
Spheroplasting, electroporation and the PEG/LiCl methods were all employed for the 
transformation of P. pastoris in this study.  
2.10.3 Vector preparation  
The pPIC3.5K-SRD5A1 expression vector and the parent vector pPIC3.5K, were both 
linearized with SalI prior to transformation, as digestion with SalI produces Mut+ (Methanol 
utilisation plus) transformants (116). Controls (no DNA and parent vector without insert) 
were included in all transformations reactions and were subsequently used as background 
controls for expression.  
2.10.4 Spheroplasting 
P. pastoris strain GS115 cells were picked from single colonies, grown for 2 days at 30°C on 
YPD-agar plates, and subsequently used to inoculate 10 ml of YPD medium. Starter cultures 
were grown at 30°C while shaking vigorously at 275 rpm overnight. The starter culture, 10 µl, 
was used to inoculate 200 ml YPD and the culture incubated overnight at 30°C while shaking 
at 275 rpm. Once an OD600 of 0.3 was reached the cells were centrifuged at 1500 x g for 10 
minutes at room temperature. The supernatant was discarded, the yeast cells were washed 
with 20 ml sterile water and centrifuged at 1500 x g for 5 minutes at room temperature. The 
pellet was washed in 20 ml SED (1 M sorbitol, 25 mM EDTA, pH8.0 and 50 mM DTT) and 
centrifuged at 1500 x g for 5 minutes at room temperature. The pellet was subsequently 
washed with 1 M sorbitol and centrifuged at 1500 x g for 5 minutes at room temperature. The 
pellet was resuspended in 20 ml of SCE (1M sorbitol, 1 mM EDTA and 10 mM sodium 
citrate buffer, pH5.8) by swirling. Zymolase
TM
, 37.5 U, was added to 10 ml cell suspension in 
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a clean centrifuge tube and incubated for 30 minutes at 30°C in order to achieve 70% 
spheroplasting. The spheroplasts were harvested by centrifugation at 750 x g for 10 minutes at 
room temperature. Spheroplasts were subsequently washed with 10 ml 1M sorbitol, collected 
by centrifugation at 750 x g for 10 minutes at room temperature and washed once with 10mL 
CaS (1 M sorbitol, 10 mM Tris-HCl, pH 7.5 and 10 mM CaCl2). The spheroplasts were 
harvested by centrifugation and gently resuspended in 600 µl CaS.  
Spheroplasts, 100 µl, were prepared in 15 ml snap cap falcon tubes and linearized plasmid 
(pPIC3.5K-SRD5A1, pPIC3.5K), 10 µg, was added to the spheroplasts and to 100 µl sterile 
water (negative controls). Reaction mixtures were incubated at room temperature for 10 
minutes. Freshly prepared PEG/CaT, 1 ml, (1:1, 40% PEG and CaT (20 mM Tris-HCl, pH 
7.5; 20 mM CaCl2)), was added to the cells (100 µl) and incubated for a further 10 minutes. 
Cells were centrifuged at 750 x g for 10 minutes at room temperature and the PEG/CaT 
removed by aspiration. SOS medium (1 M sorbitol, 0.3X YPD, 10 mM CaCl2), 150 µl, was 
subsequently added and the mixture was incubated at room temperature for 20 minutes. 1 M 
sorbitol, 850 µl, was added to each of the transformations prior to plating.  
All transformations were plated using top cell wall regeneration media (RDB) (1 M sorbitol, 
2% dextrose, 1.34% YNB without amino acids, 0.00004% biotin and 0.005% amino acids (L-
glutamic acid, L-methionine, L-lysine, L-leucine and L-isoleucine)) by adding 200 µl of each 
transformation cocktail to 10 ml molten RD agar before pouring onto a RDB agar plate. The 
viability and selection of positive transformants was accomplished due to the absence of 
histidine on these plates (116). Plates were inverted and incubated for 4 days at 30°C. 
Untransformed spheroplasts were plated on RDBH (regeneration plates containing 0.004% 
histidine) plates in order to confirm the viability of the spheroplasts.  
2.10.5 Electroporation 
YPD culture, 10 ml, was inoculated with a single fresh colony of P. pastoris GS115 grown on 
an YPD-agar plate, and subsequently incubated overnight at 30°C shaking at 275 rpm. Fresh 
YPD medium, 500 ml, was inoculated with the starter culture and incubated in a 2 l baffled 
flask at 30°C shaking at 275 rpm until an OD600 of 1.5 was reached. Yeast cells were 
harvested by centrifugation at 1500 x g for 5 minutes at 4°C and resuspended in 500 ml of ice-
cold sterile water. Cells were collected by centrifugation 1500 x g for 5 minutes at 4°C and 
resuspended in 250 ml of ice-cold sterile water. Cells were collected by centrifugation at 1500 
x g for 5 minutes at 4°C and resuspended in 20 ml ice-cold 1 M sorbitol.  Cells were again 
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collected by centrifugation at 1500 x g for 5 minutes at 4°C and resuspended in 1 ml ice-cold 
1 M sorbitol (final volume ± 1.5 ml).  
Electro-competent cells, 80 µl, were mixed with 10 µl linearized DNA (10 µg), transferred to 
an ice cold electroporation cuvette (0.2 cm) and incubated on ice for 5 minutes. 
Electroporation was subsequently carried out using savant GTF100 gene transformer which 
was set to 1800 V and initiated by holding the pulse button for 10 seconds. Following 
electroporation 1 mL ice-cold 1 M sorbitol was immediately added to the cuvette and the 
contents to a sterile microcentrifuge tube and incubated at 30°C without shaking for 90 
minutes. Transformed cells, 100 µl, were subsequently spread on MD (Hisˉ) plates for the 
selection of positive transformants. Plates were inverted and incubated for 5 days at 30°C 
until colonies formed.  
2.10.6 PEG/LiCl procedure 
YPD media, 10 ml, was inoculated with a single P. pastoris strain GS115 colony grown on a 
YPD-agar plate (previously incubated for 2 days at 30°C), and grown overnight at 30°C while 
vigorously shaking at 275 rpm. Cells were centrifuged at 3000 rpm for 2 minutes before 50 µl 
of cells were transferred to a 1.5 ml microcentrifuge tube. Sterile deionised water, 1 ml, was 
added to the cells and centrifuged at 13000 rpm for 30 seconds. The water was discarded and 
the pellet resuspended in 100 mM LiCl, 1 ml, and incubated at 30°C for 5 minutes without 
shaking. A cell suspension, 50 µl, was subsequently transferred to a sterile round bottom 
microcentrifuge tube, centrifuged at 13000 rpm in a bench top centrifuge for 20 seconds and 
the supernatant discarded. The following reagents were subsequently added sequencially; 240 
µl 50% PEG1000; 26 µl of 1M LiCl; 25 µl salmon sperm DNA (2 mg/ml); and 5 µg plasmid 
DNA in a volume of 50 µl. The cocktail was mixed thoroughly by vortexing and incubated in 
a water bath at 42°C for 25 minutes. Cells were centrifuged at 13000 rpm for 20 seconds and 
resuspended in sterile water before plating 150 µl onto MD (Hisˉ) plates. Plates were inverted 
and incubated at 30°C for 5 days.    
2.11 Screening of P. pastoris GS115/pPIC3.5K-SRD5A1 and GS115/pPIC3.5K 
positive transformants 
Successful transformation was achieved using the PEG/LiCl method. Positive transformants 
grown on MD plates, lacking histidine, were pooled and re-plated on YPD-G418 plates in a 
G418 concentrations range (0.25, 0.5, 0.75 and 1.0 mg/ml). The level of G418 resistance has 
Stellenbosch University  https://scholar.sun.ac.za
 
 
34 
been shown to correlate to the number of copies of the kanamycin gene incorporated into the 
yeast genome (119). A single copy of pPIC3.5K plasmid integrated into the genome confers 
resistance to 0.25 mg/ml G418 (116). These plates were inverted and incubated at 30°C for 4 
days. 
The integration of the SRD5A1 cDNA into the P. pastoris genome was subsequently 
confirmed by PCR amplification analysis. Single colonies picked from YPD-G418 plates and 
suspended in sterile water (30 µl) prior to the addition of 100 U of lyticase (crude, from 
Arthrobacter luteus) (120). The mixture was incubated at 30°C for 12 minutes to allow 
digestion of the cell wall. The cells were then flash frozen in liquid nitrogen for 1 minute and 
the lysate was used as a template for the PCR amplification.  
Each PCR amplification mixture (50 µl) contained: the appropriate reaction buffer containing 
MgCl2 (25 mM); 200 µM of each dNTP; 0.25 µM of each primer (AOX1 and SRD5A); 2.5 U 
of Pfu polymerase (10 U/µl); and 5 µl crude cell lysate. The amplification profile was as 
follows: (1) denaturing of the template at 94°C for 1 minutes; (2) 35 cycles of denaturing at 
94°C for 1 minute, annealing at 55°C for 1 minute and extension at 72°C for 1 minute; (3) and 
a final extension at 72°C for 7 minutes. Amplicons were separated and analysed on a 1% 
agarose gel by electrophoresis. Positive colonies were grown overnight at 37°C while shaking 
at 200 rpm and freezer stocks were prepared in 15% glycerol and stored at -80°C.  
2.12 Endogenous steroid metabolism by P. pastoris 
The endogenous steroid metabolism of P. pastoris was firstly investigated as 3α- or 3β-
hydroxysteroid dehydrogenase activity has been reported in S. cerevisiae (75) and may, as 
such, interfere with analysis of SRD5A products in this study. A starter culture grown in 
BMGY medium for 20 hours was used to inoculate a baffled flask containing 25 ml BMMY 
to an OD600 of 1 (5x10
7
 cells/ml). The culture was incubated at 200 rpm for 48 hours at 30°C. 
Methanol (0.5% v/v) was added every 24 hours. The metabolism of steroid substrates, T, 
11OHT, 11KT, 11OHA4, 11KA4 and DHT was subsequently assayed. Cells were harvested 
by centrifugation at 2000 x g for 5 minutes at RT, washed with PBS and resuspended in 1 ml 
fresh BMMY media to an OD600 of 1x10
8
. After a 15 minute pre-incubation at 30°C, steroid 
(1 µM final concentration) in BMMY media was added in an equal volume (1 ml). Aliquots, 
500 µl, were removed at specific time intervals, 0, 30, 60 and 120 minutes to analyse substrate 
conversion. Steroids were extracted and analysed as described in section 2.5 and 2.6.  
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2.13 The selection of optimal SRD5A1 expression in P. pastoris by substrate 
conversion assays.  
The pPIC3.5K-SRD5A1 vector was successfully incorporated into the yeast genome 
with clones demonstrating different copy numbers. Each of the transformants were screened 
for the ability to metabolise T to DHT to determine which clone exhibited the highest 
SRD5A1 activity. A single pPIC3.5K-SRD5A1 transformant colony from each of the 0.25, 
0.75 and 1.0 mg/ml G418 plates (S0.25, S0.75 and S1.0), as well as a single parent vector 
transformant colony from the a 0.25 mg/ml G418 plate (P0.25; control), were inoculated in 25 
ml of BMGY medium and incubated at 30°C while shaking at 275 rpm for 18 hours. The cells 
were grown to an OD600 of 4, collected by centrifugation and resuspended in BMMY to a cell 
density equivalent to that of an OD600 of 1. The cultures, 200 ml each, were subsequently 
grown at 30°C, shaking at 275 rpm for a total of 98 hours. Aliquots, 1 ml, were taken at 0, 24 
and 48 hours in order to monitor growth rate. Methanol, 0.5% v/v, was added every 24 hours.  
The metabolism of T was assayed after 48 hours as follows. Cells were harvested by 
centrifugation, 2000 x g for 5 minutes at RT, washed with PBS and resuspended in 1 ml fresh 
BMMY media to an OD600 of 1 (5x10
7
 cells/ml). After a 15 minute pre-incubation at 30°C in 
a 6 well culture plate, steroid (1 µM final concentration) in BMMY media was added in an 
equal volume of 1 ml. Aliquots, 500 µl, were removed at specific time intervals, 30, 60, 120 
and 240 minutes to analyse substrate conversion. Control reactions were performed using 
cells containing the parent vector. Steroids were extracted and analysed as described in 
section 2.5 and 2.6.  
2.14 C19 steroid metabolism by P. pastoris expressing SRD5A1 
Single colonies of P. pastoris strain GS115 expressing SRD5A1 were grown in 200 ml 
BMGY growth medium for 24 hours at 30°C in a shaking incubator at 275 rpm. Yeast cells 
were collected by centrifugation at 2000 x g for 5 minutes and subsequently resuspended in 
BMMY induction medium to an OD600 of 1 (5x10
7
 cells/ml). The cells were subsequently 
incubated at 30°C, shaking at 275 rpm, for an additional 48 hours. Methanol (0.5% v/v) was 
supplemented at 24 hours. The metabolism of C19 steroids was subsequently assayed as 
follows: Cells were harvested by centrifugation, 2000 x g for 5 minutes at RT, washed with 
PBS and resuspended in 1 ml fresh BMMY media to an OD600 of 1 (5x10
7
 cells/ml). After a 
15 minute pre-incubation period at 30°C in a 6 well culture plate, steroid (30 µM final 
concentration) in BMMY media was added in an equal volume of 1 ml. Aliquots, 500 µl, 
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were removed at specific time intervals, 30, 60, 120 and 240 minutes to analyse substrate 
conversion. Control reactions were performed using cells transformed with the parent vector. 
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Chapter 3 
RESULTS 
3.1 Analyses of C19 steroid conversion by SRD5A1 expressed in HEK-293 cells  
SRD5A1 expressed in HEK-293 cells catalysed the conversion of 1µM 11OHA4, 11KA4, 
11OHT and 11KT in 48 hours with no substrate remaining, as confirmed by UPLC-MS/MS. 
Figure 3.1 shows a chromatogram for the conversion of 11OHA4 to 11OH-5α-dione by 
SRD5A1. Figure 3.2 shows the negative control in which no 11OHA4 was converted to 
11OH-5α-dione.   
Figure 3.1 Conversion of 1 μM 11OHA4 (A) to 11OH-5α-dione (B) by SRD5A1 expressed in HEK-293 cells. 
Peak at retention time (RT) 3.55 minutes indicated on (B) shows 11OH-5α-dione formation and lack of peak at 
3.12 minutes on (A) indicates full conversion of 11OHA4. 
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Figure 3.2 Negative control for the conversion of 1µM 11OHA4 (A) to 11OH-5α-dione (B) by pCIneo (no 
SRD5A1 expressed) transfected HEK-293 cells. RT 3.12 minutes on (A) indicates no conversion was observed 
as all of the substrate remains. No product peak is seen at RT 3.55 minutes in (B).  
Response factors were determined for the SRD5A products, 11OH-5α-dione, 11K-5α-dione, 
11OHDHT and 11KDHT, so that these products could be quantified using the standard curves 
obtained for their respective substrates. These response factors were determined by comparing 
the area under the peak for 1 µM substrate to that of 1 µM product. This allowed for the 
products to be quantified from the standard curves obtained for the substrate. The response 
factors are listed below in table 3.1.  
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
39 
Table 3.1 Response factors for the SRD5A1 products 11OH-5α-dione, 11K-5α-dione, 11OHDHT and 11KDHT. 
Response factors are calculated by dividing the area of the substrate over area of internal standard by the area of 
product over the area of internal standard. Results are shown as the average ± standard deviation, n=6. 
Products 11OH-5α-dione 11K-5α-dione 11OHDHT 11KDHT 
Substrates     
11OHA4 4.147±0.640    
11KA4  4.501±0.549   
11OHT   3.812±0.243  
11KT    2.973±0.179 
The response factors determined above allowed for the quantification of the SRD5A1 
products investigated in this study. Time course experiments were first performed using 
HEK-293 cells expressing SRD5A1 and a single substrate concentration of 5 μM. The 
SRD5A1 catalysed metabolism of A4 and T to 5α-dione and DHT, respectively, is shown in 
figure 3.3. The metabolism of 11OHA4, 11KA4, 11OHT and 11KT by SRD5A1, as 
determined using the response factors (table 3.1), to 11OH-5α-dione, 11K-5α-dione, 
11OHDHT and 11KDHT, respectively, is shown in figure 3.4. The data shown in figures 3.3 
and 3.4 represent different experiments and cannot be compared directly to each other.  
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Figure 3.3 Time course for the metabolism of 5µM (A) T and (B) A4 by SRD5A1 expressed in HEK-293 cells. 
Three independent experiments were performed in triplicate. Representative results are from a single experiment 
performed in triplicate and are expressed as ±SEM. 
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Figure 3.4 Time course for the metabolism of 5µM (A) 11OHA4, (B) 11KA4, (C) 11OHT and (D) 11KT by 
SRD5A1 expressed in HEK-293 cells. The results are from a single experiment performed in duplicate and are 
expressed as ±SD. 
A4 was utilised more readily than T within the same experiment, as seen in figure 3.3. After 2 
hours 95% of A4 was converted to 5α-dione, while only 78.5% T was converted to DHT. A 
similar, but more pronounced trend was observed with the 11-oxygenated steroid substrates. 
After 5 hours, both 11OHA4 and 11KA4 were converted to 91.8% and 94.7% of their 
respective products. During the same period only 32.3% of 11OHDHT and 42.4% of 
11KDHT was formed from the metabolism of 11OHT and 11KT, respectively (figure 3.4). 
While this data gave an indication of the substrate preferences of SRD5A1, kinetic parameters 
needed to be determined before any conclusions could be drawn.  
3.2 The kinetic characterisation of SRD5A1 
Time course experiments were conducted in HEK-293 cells expressing SRD5A1 as the cell 
line has no significant endogenous steroidogenic activity which would influence the data 
obtained. The substrates A4, T, 11OHA4, 11KA4, 11OHT and 11KT were assayed at 0.5, 5.0 
and 30µM in order to generate progress curves which could be used for the kinetic 
characterisation of SRD5A1. Transfection efficiency varies in individual experiments, 
influencing the kinetic parameters. As the enzyme concentration is directly proportional to the 
initial rate of conversion for a given substrate concentration, the conversion of 5 µM T was 
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included in all experiments as a reference. The initial rate for the conversion of 5 µM T was 
used as a scaling factor for the subsequent determination of kinetic parameters.  
.  
Figure 3.5 Determination of the initial rate for the metabolism of 5µM T by SRD5A1 expressed in HEK-293 
cells.  
The initial rates indicated in table 3.2 were determined for the control reactions (5µM T) in 
each of the progress curve experiments and were used to normalise the experiments during 
subsequent kinetic parameter determinations.  
Table 3.2 Initial reaction rates for the 5µM T control reactions for the respective progress curve time courses. 
Initial reaction rate (µM/h) Substrates   
3.1949 0.5µM and 5µM A4 
0.6494 0.5µM T 
1.0839 0.5µM and 5µM 11OHA4 and 11KA4 
0.9889 0.5µM 11OHT and 11KT 
3.5517 5µM 11OHT and 11KT 
1.4766 30µM all substrates 
y = 1.0839x 
R² = 0.9929 
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Figures 3.6 – 3.11 below show the experimental time course data (0.5, 5 and 30 μM) for each 
of the SRD5A1 substrates investigated in this study as well as the fitted data obtained using 
the objective function (S, substrates; E, experimental substrate values; M, model predicted 
substrate values): 
∑(
             
      
)
  
   
 
The Michaelis-Menten equation was used as a model for the predicted change in S. The 30 
μM assays were performed over a period of 4 hours in order to determine the Vmax of 
SRD5A1 for each of its substrates. These 30 μM assays were therefore all performed in the 
same experiment in order to compare the Vmax directly.  
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Figure 3.6 Progress curve analysis of A4 metabolism by SRD5A1 expressed in HEK-293 cells. The initial 
substrate concentrations were (A) 0.5µM, (B) 5.0µM and (C) 30µM. Experimental data is shown by the 
individual data points and the fitted data is shown with solid lines. Each time course is from a single experiment 
performed in triplicate and is expressed as ±SD. 
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Figure 3.7 Progress curve analysis of T metabolism by SRD5A1 expressed in HEK-293 cells. The initial 
substrate concentrations were (A) 0.5µM, (B) 5.0µM and (C) 30µM. Experimental data is shown by the 
individual data points and the fitted data is shown with solid lines. Each time course is from a single experiment 
performed in triplicate and is expressed as ±SD. 
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Figure 3.8 Progress curve analysis of 11OHA4 metabolism by SRD5A1 expressed in HEK-293 cells. The initial 
substrate concentrations were (A) 0.5µM, (B) 5.0µM and (C) 30µM. Experimental data is shown by the 
individual data points and the fitted data is shown with solid lines. Each time course is from a single experiment 
performed in triplicate and is expressed as ±SD. 
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Figure 3.9 Progress curve analysis of 11KA4 metabolism by SRD5A1 expressed in HEK-293 cells. The initial 
substrate concentrations were (A) 0.5µM, (B) 5.0µM and (C) 30µM. Experimental data is shown by the 
individual data points and the fitted data is shown with solid lines. Each time course is from a single experiment 
performed in triplicate and is expressed as ±SD. 
Stellenbosch University  https://scholar.sun.ac.za
 
 
47 
 
Figure 3.10 Progress curve analysis of 11OHT metabolism by SRD5A1 expressed in HEK-293 cells. The initial 
substrate concentrations were (A) 0.5µM, (B) 5.0µM and (C) 30µM. Experimental data is shown by the 
individual data points and the fitted data is shown with solid lines. Each time course is from a single experiment 
performed in triplicate and is expressed as ±SD. 
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Figure 3.11 Progress curve analysis of 11KT metabolism by SRD5A1 expressed in HEK-293 cells. The initial 
substrate concentrations were (A) 0.5µM, (B) 5.0µM and (C) 30µM. Experimental data is shown by the 
individual data points and the fitted data is shown with solid lines. Each time course is from a single experiment 
performed in triplicate and is expressed as ±SD. 
The determined kinetic parameters are shown below in table 3.3. Interestingly a 1.8-fold 
difference was observed in the affinity of SRD5A1 for A4 and T, with SRD5A1 
demonstrating a higher affinity for T (Km = 3.73 μM) than A4 (Km = 6.76 μM). This 
contradicts previous studies (86) performed in stably transfected HEK-293 cells in which 
SRD5A1 demonstrated a higher affinity for A4 (Km = 3.5±0.5 μM) than for T (Km = 12.0±1.8 
μM). Possible reasons for this discrepancy will be discussed in detail in chapter 4. The Vmax 
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obtained for A4 was 2-fold higher than that of T (table 3.3), which is in agreement with 
previous studies (81). Vmax/Km is a better estimation of catalytic efficiency (121). True 
enzyme efficiency (Kcat/Km) cannot be utilised here as the determination of Kcat (maximum 
number of enzymatic reactions per second) requires purified enzyme. Vmax/Km shows that 
SRD5A1 has a similar catalytic efficiency towards A4 (Vmax/Km = 0.59) and T (Vmax/Km = 
0.55), illustrated in figure 3.3. When considering the enzymatic activity of SRD5A1 towards 
the novel substrates, 11OHA4 is the preferred substrate as its catalytic efficiency is 2-fold 
greater than that of 11KA4. The conversion of T is more efficient than 11OHT and 11KT as 
the catalytic efficiency was 10-fold greater for T. The metabolism of 11OHT and 11KT was 
also considerably less efficient than for the C11 hydroxy and keto A4 derivatives as reflected 
in the 6.6 and 3.4-fold lower catalytic efficiency, respectively. This suggests that the flux 
through the 11OHA4 pathway would favour the reduction of 11OHA4 and 11KA4 by 
SRD5A1 rather than that of 11OHT and 11KT, thereby mirroring the flux through the 
5α-dione pathway. 
Table 3.3 Vmax and Km values generated by progress curve analysis (figures 3.6 - 3.11).  
 Substrates Vmax (µM/h) Km (µM) Vmax/Km 
A4 4.0 6.8 0.59 
T 2.1 3.7 0.55 
11OHA4 3.1 9.3 0.33 
11KA4 5.9 35.2 0.17 
11OHT 3.9 72.1 0.05 
11KT 4.8 100* 0.05 
*No satisfactory optimal solution was found.  
3.3 Analyses of SRD5A integration into the pPIC3.5K expression vector 
The plasmids SRD5A1-pCMV7 and pPIC3.5K were successfully purified. PCR amplification 
of SRD5A1 cDNA from the SRD5A1-pCMV7 plasmid yielded a 850bp amplicon. SRD5A1 
cDNA is 820bp in size, however, the addition of the Kozak sequence and the flanking EcoRI 
restriction cut sites comprised 30 bp. Figure 3.12 shows the analysis of the PCR amplification 
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on a 1% agarose gel indicating the SRD5A1 DNA fragment was successfully amplified. No 
DNA fragment was obtained in the negative control PCR amplification.  
 
Figure 3.12 1% agarose gel analysing the PCR amplification of SRD5A1 cDNA. Lane 2: 1kb DNA marker 
(Promega) Lane 4: SRD5A1 PCR reaction Lane 5: negative PCR control. 
The amplified SRD5A1 cDNA was subsequently cloned into the pPIC3.5k vector and 
transformed into DH5α E.coli cells. Plasmid DNA was isolated from transformed colonies 
and subjected to restriction enzyme digestion with NcoI in order to identify positive clones as 
well as to analyse the orientation of the cDNA insert. Figure 3.13 shows the analysis of the 
restriction enzyme digest on a 1% agarose gel.  
Lanes 4 show DNA fragments with sizes (2350 bp and 7400 bp) that were calculated for the 
NcoI digest of the pPIC3.5k vector containing the human SRD5A1 cDNA insert orientated in 
the 3ʹ-5ʹ direction, while lane 7 shows DNA fragments with sizes (3150 bp and 6600 bp) 
which indicate the desired 5ʹ-3ʹ orientation of the insert. DNA sequencing confirmed that the 
positive clone identified in lane 7 contains the cDNA encoding human SRD5A1 (GenBank 
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assession number E.C 1.3.1.22) in correct orientation, and that the cDNA is in reading frame 
for functional expression. 
 
Figure 3.13 1% agarose gel analysing the restriction digest analysis of pPIC3.5K vector containing the 
SRD5A1. Lane 1: 1kb DNA marker (Promega). Lanes 2, 3, 5, 6 and 8: NcoI digest of vector only; Lane 4: 
NcoI digest of a positive clone with containing SRD5A1 in the 3ʹ-5ʹ orientation; Lane 7: NcoI digest of a 
positive clone with containing SRD5A1 in the 5ʹ-3ʹ orientation. 
3.4 Identification of SRD5A1 P. pastoris Transformants  
Transformation of P. pastoris with pPIC3.5K-SRD5A1 plasmid using the spheroplasting and 
electroporation transformation methods proved to be unsuccessful. Successful transformation 
was, however, achieved using the PEG/LiCl method. Primary selection was carried out using 
minimal medium, Hisˉ plates. Only transformants which gained the ability to produce 
histidine (histidine positive (his
+
) phenotype) were able to grow on these plates.  
Positive clones obtained from the first round of selection were subsequently pooled for a 
secondary selection process on G418-YPD plates containing increasing concentrations of 
G418. The concentration of G418 plates on which transformants survive correlate with the 
copy number expression cassette integration into the yeast genome (115). Resistance observed 
using plates containing 0.25 mg/ml G418 is indicative of a single copy of the expression 
cassette being integrated into the yeast genome. SRD5A1 transformants were observed on the 
0.25, 0.5, 0.75 and 1.0 mg/ml G418 plates (figure 3.14).  
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Figure 3.14 SRD5A1 transformed P. pastoris plated on agar with increasing geneticin concentrations. The 
degree of resistance correlates to the number of SRD5A1 copies integrated into the yeast genome. (A) 0.25 
mg/ml G418 indicating at least 1 copy integration. (B) 0.5 mg/ml G418, growth on this plate indicates 1-2 copy 
number integration. (C) 0.75 mg/ml G418, 2 or more copy integration and (D) 1.0 mg/ml G418 also indicates 2 
or more copy integration.  
Single colonies were selected from each plate, termed S 0.25, S 0.5, S 0.75 and S 1.0, 
respectively and used to inoculate starter cultures. Parent vector transformants were only able 
to grow on the 0.25 mg/ml G418 plates (figure 3.15). A single colony, P 0.25, was selected. 
 
Figure 3.15 pPIC3.5K transformed P. pastoris plated on increasing concentrations of G418. (A) 0.25 mg/ml 
G418, single copy integration minimum for growth on these plates. 0.5 (B), 0.75 (C) and 1.0 (D) mg/ml G418 
respectively, however no growth of parent vector was observed on these plates.   
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Further confirmation of the successful integration of SRD5A1 into the yeast genome was 
obtained by PCR analysis of crude yeast lysates. Figure 3.16 shows the successful 
amplification of SRD5A1 cDNA from the yeast genome of all positive transformants (Lanes 
2-4 and 6-9) with exception of the transformant seen in lane 5. The size of the amplicons 
correlated with the amplicon obtained in the positive control (lane 10) representing the 
purified SRD5A1-pPIC3.5k plasmid template. Integration of SRD5A1 into the genome of 
GS115 strain P. pastoris was thus confirmed.  
 
Figure 3.16 1% agarose gel analysing the direct PCR amplification screening of GS115/pPIC3.5K-SRD5A1 
clones. Lane 1: Negative control – amplification of yeast transformed with pPIC3.5k vector containing no 
SRD5A1 insert; lane 2 and 3: PCR amplification of positive transformants grown on 1.0 mg/ml G418-YPD 
selection plates; lane 4 and 5: PCR amplification of positive transformants grown on 0.75 mg/ml G418-YPD 
selection plates; lane 6 and 7: PCR amplification of positive transformants grown on 0.5 mg/ml G418-YPD 
selection plates; lane 8 and 9: PCR amplification of positive transformants grown on 0.25 mg/ml G418-YPD 
selection plates. Lane 10: Positive control - PCR amplification of purified pPIC3.5K-SRD5A1 plasmid (100ng). 
Lane 11: 1kb DNA marker.  
PCR analysis of crude yeast lysates were also performed using AOX1 primers. These primers 
result in the amplification of the AOX gene (214bp) and the cloned gene of interest. As the 
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gene of interested is inserted into the AOX gene, amplification with AOX primers can also 
detect the integration of multiple copy numbers. Figure 3.17, lane 2, shows the amplification 
of a single copy of the AOX1 gene (214 bp) from yeast transformed with the parent vector 
(pPIC3.5k). Lane 3 shows the amplification of a single copy of the AOX (214 bp) with the 
integrated SRD5A1 (850 bp ) cDNA resulting in a band of approximately 1000 bp. Lanes 3-6 
show bands of approximately 2200 bp (genomic AOX gene amplification product) indicating 
that these transformants grown on YPD plates containing 0.5, 0.75 and 1.0 mg/ml G418 have 
a mut+ phenotype.   
 
Figure 3.17 1% agarose gel analysing the direct PCR amplification screening of GS115/pPIC3.5K-SRD5A1 and 
pPIC3.5K transformants using AOX1 gene primer set. Lane 1: 1kb DNA marker. Lane 2: PCR amplification of 
positive Parent vector (pPIC3.5k) transformant grown on a 0.25 mg/ml G418-YPD plate; Lanes 3 – 6 PCR 
amplification of positive SRD5A1 transformants grown on 0.25, 0.5, 0.75 and 1.0 mg/ml G418-YPD plates, 
respectively.   
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3.5 Analysis Determination of endogenous steroid metabolism of P. pastoris 
The endogenous enzymatic activity of P. pastoris towards C19 steroids was assessed. Figure 
3.18 shows that P. pastoris was unable to metabolise SRD5A1 substrates, T, 11OHA4, 
11KA4, 11OHT and 11KT, within a 2 hour incubation period. The cells did, however, 
metabolise the 5α-reduced steroid, DHT, to an unknown product. These results are in 
agreement with studies conducted in the yeast S. cerevisiae which demonstrated endogenous 
3α- or 3β-hydroxysteroid dehydrogenase activity which was able to metabolise DHT (75, 
100).  
 
Figure 3.18 Endogenous steroid metabolism by P. pastoris strain GS115.  Cells were incubated with 1µM 
substrate for 2 hours. DHT was utilised by an endogenous yeast enzyme(s). The results are from a single 
experiment performed in triplicate and are expressed as ±SD. Data was analysed by a 1way ANOVA followed 
by a Bonferroni’s Multiple Comparison post-test. (***P<0.001, ns=not significant, n=3). 
3.6 Analyses of experimental protocol optimisation Selection for optimal SRD5A1 
activity in P. pastoris 
The growth of SRD5A1 transformants selected in section 3.4 was assessed during an 80 hour 
induction period with methanol. Figure 3.19 show that the methanol induced expression of 
SRD5A1 does not negatively affect the growth of any of the transformants.  
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Figure 3.19 Growth curves of GS115 transformants during induction phase. Growth of transformants with 
different copy number integrations was monitored after the addition of methanol (0.5%, v/v final concentration). 
Methanol was added every 24 hours to maintain induction. The results are from a single experiment performed 
in triplicate and are expressed as ±SEM. 
SRD5A1 transformants were screened for SRD5A1 activity by completing a time course 
assay with T as a substrate. Figure 3.20 shows that the parent vector transformant P 0.25 was 
unable to metabolise the T substrate. All SRD5A transformants, however, were able to 
metabolise T. As expected, the single copy number transformant, S 0.25, showed the least 
SRD5A1 activity. The S 0.75 and S 1.0 transformants which both contain two copies of the 
SRD5A1 cDNA (section 3.4) exhibited similar activity towards T. S 0.75 showed marginally 
higher activity than S 1.0 and was therefore chosen for all further experiments. Taken together 
these results show the successful expression of functional human SRD5A1 in the P. pastoris 
yeast expression system.  
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Figure 3.20 Time course of T metabolism by SRD5A1 activity in transformed P. pastoris. T (1µM) was assayed 
in the S 0.25, S 0.75, S 1.0 and P 0.25 transformants. The results are from a single experiment performed in 
duplicate and are expressed as ±SD. 
3.6 Analysis of C19 steroid metabolism by P. pastoris expressing SRD5A1  
Figure 3.21 shows that both T and A4 are effectively metabolised by P. pastoris expressing 
SRD5A1. A4 is, however, metabolised more efficiently than T when using 30μM substrate. 
50% of A4 is converted within 30 minutes with negligible formation of AST, thus primarily 
indicating the catalytic activity of SRD5A1. At this time ±25% of T was metabolised by 
SRD5A1. This result, obtained under saturating substrate concentrations, is in agreement with 
the observations made in section 3.2 that Vmax of A4 is 2-fold that of T (table 3.3) as well as 
from previous studies (61). Figure 3.21(A) shows that while T was efficiently metabolised, 
the 5α-reduced product DHT did not accumulate, indicating that this steroid presented as a 
substrate for a secondary reaction catalysed by an endogenous yeast enzyme. 3α- or 3β-
hydroxysteroid dehydrogenase activity has previously been observed S. cerevisiae (75, 100). 
Conversion of 5α-dione to androsterone (AST) was detected when A4 was used as a 
substrate, suggesting endogenous HSD3A activity (figure 3.21B). Interestingly, the 5α-
reduced product of A4, 5α-dione, increased during the metabolism of A4 suggesting that the 
endogenous HSD3A activity does not favour 5α-dione as a substrate (figure 3.21B). In 
contrast, DHT did not accumulate with levels remaining negligible during the course of the 
assay, indicating that DHT is the preferred substrate for the endogenous enzymatic activity.  
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Figure 3.21 Metabolism of T (A) and A4 (B) by P. pastoris expressing SRD5A1. Two independent experiments 
were performed. Representative results are shown from a single experiment performed in triplicate and are 
expressed as ±SD. 
Figure 3.22 shows the metabolism of 11OHA4, 11KA4, 11OHT and 11KT by the SRD5A1 
transformant S 0.75. The A4 C11-derivatives, 11OHA4 and 11KA4, were utilised more 
readily by SRD5A1 than the T C11-derivatives, 11OHT and 11KT. Within 15 minutes 50% 
of 11KA4 was used while 50% of 11OHA4 was utilised after 30 minutes. In contrast, only 
34.5% 11OHT and 52.5% 11KT were metabolised in 2 hours.  
The trend observed between 11OHA4 and 11KA4 metabolism by SRD5A1 expressed in the 
HEK293 cells is not as prominent. The progress curves thus do not reflect what is observed 
for 11OHA4 and 11KA4 in the yeast model. The substantial difference between the A4 and T 
derivatives was, however, consistent in both models. The concentration of substrate measured 
after a 2 hour incubation of the C19 steroids with the P 0.25 control did not change 
significantly, confirming that substrate conversion was due to SRD5A1 activity.  
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Figure 3.22 Metabolism of 11OHA4 (A), 11KA4 (B), 11OHT (C) and 11KT (D) by SRD5A1 expressed in P. 
pastoris. The results are from a single experiment performed in triplicate and are expressed as ±SD. 
Interestingly, the endogenous enzyme’s activity was able to utilise the 5α-reduced steroids as 
substrates as indicated by the lack of accumulation of product. 11K-5α-dione was more 
readily converted by endogenous HSD3A as the profile of the time course assay for the 
steroid is downward compared to that of 11OH-5α-dione after 2 hours. The 5α-reduced 
products of 11OHT and 11KT do not accumulate as the A4 derivatives, however, this could 
be a result of the lower rate of conversion of 11OHT and 11KT to their respective 5α-reduced 
products or due to endogenous HSD3A preference for T derivatives over the A4 derivatives. 
This trend is similar to observations seen for 5α-dione and DHT in figure 3.21. 
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Chapter 4 
DISCUSSION 
 
The SRD5A enzymes are responsible for converting androgenic steroids and androgen 
precursors to potent androgens (16). The most well-known reaction which SRD5A catalyses 
is the conversion of T to DHT. Abrogation of SRD5A2 activity during early developmental 
stages causes a disruption in male sexual differentiation in the embryonic urogenital tract (16, 
90). DHT is not available to initiate the differentiation of male the external genitalia and 
prostate gland (71). The importance of SRD5A in the development and growth of the healthy 
prostate was clearly established as a result of this genetic disease (16, 122).  
As prostate cancer and CRPC are androgen dependent, SRD5A, plays an equally important 
role in the development and progression of these diseases. Interestingly though, while 
SRD5A2 expression is predominant in the healthy prostate, studies have shown that it is 
SRD5A1 which is upregulated during CRPC development, while SRD5A2 is downregulated 
in this disease (123). Steroid conversion assays in mammalian cells expressing SRD5A have 
clearly demonstrated that while SRD5A1 has a lower affinity for T than SRD5A2, SRD5A1 
has a substantially higher Vmax (61). SRD5A1, however, favours the conversion A4 over T. 
The upregulation of SRD5A1 expression during CRPC therefore gives the tumour the ability 
to use the adrenal androgen precursor A4 as a substrate for DHT formation via the alternate 
5α-dione pathway, which bypasses T (58). The recent identification of the 11OHA4 pathway 
has introduced four new substrates, 11OHA4, 11KA4, 11OHT and 11KT, for intratumoral 
metabolism via SRD5A1 (47, 57). SRD5A1 has been shown to convert all four substrates into 
novel 5α-reduced androgens (47). These were shown to be capable of activating the wild type 
human AR to differing degrees. The androgenic activity of 11KT was comparable to that of 
T, while 11KDHT demonstrated androgenic activity comparable to that of DHT, the “most 
potent” natural androgen (47, 65).  
Other enzymes, which include HSD17B and HSD3A, are present in the healthy prostate and 
are upregulated during CRPC. These enzymes metabolise 5α-dione pathway metabolites and 
have more recently been shown to play a vital role, together with HSD11B2, in the 11OHA4 
pathway (47, 57). Although SRD5A1 is therefore not the only enzyme in the 11OHA4 
pathway metabolising adrenal C19 steroids, the characterisation of SRD5A1 towards 
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11OHA4, 11KA4, 11OHT and 11KT will provide insight into the preferred steroid flux in the 
11OHA4 pathway. The subsequent characterisation of HSD11B2, HSD17B and HSD3A 
enzymes will allow for the development of a computational model for the conventional C19 
pathway, the 5α-dione pathway and the 11OHA4 pathway. This will greatly enhance our 
understanding of intratumoral androgen metabolism and will aid in the identification of more 
suitable drug targets. 
The first part of this study was conducted with HEK-293 cells, a mammalian model which has 
been shown to be suitable for the expression of all the relevant steroidogenic enzymes, 
including SRD5A1 (57, 102, 103, 124). The novel 5α-reduced metabolites produced in the 
11OHA4 pathway are not, however, commercially available, creating a hurdle for the 
quantification of these C19 steroids. This problem was overcome by determining response 
factors for these 5α-reduced steroids so that they could be quantified using standard curves 
generated for their substrates. This was possible as multiple reaction mode (MRM) methods 
had previously been developed for these steroids (44) and since the reaction catalysed by 
SRD5A is irreversible (47, 57). The peak area for the product could therefore be related to 
that of the unconverted substrate in the control assay in order to generate a response factor. 
The accuracy of the response factors was ensured by the incorporation of internal standards 
which compensate for sample loss during the steroid extraction procedure. In this study the 
response factors were applied in the quantification of the 5α-reduced steroids produced by the 
heterologously expressed SRD5A1 in both mammalian and yeast systems. Response factors 
can in future be utilised for the quantification of novel 5α-reduced steroids metabolised by 
other enzymes such as HSD11B and HSD17B.  
During the first part of this study, SRD5A1 was expressed in HEK-293 cells and activity 
towards the six substrates from the 5α-dione and the 11OHA4 pathways were assayed.  
SRD5A1 converted A4 more readily than T when using an initial substrate concentration of 
5µM. This trend is in agreement with previous studies which have shown that SRD5A1 
catalyses the conversion of A4 more readily than that of T (46). This preference is significant 
in the post castration environment, where T is depleted, and the adrenal C19 steroids (DHEA 
and A4) are used as precursors for the production of DHT by the CRPC tumour (46). 
SRD5A1’s preference towards substrates in the 11OHA4 pathway appear to be similar to 
those substrates in the alternate pathway, where the 11-hydroxy and 11-keto derivatives of A4 
were more readily converted by SRD5A1 than the T derivatives. Performing conversion 
assays at three separate substrate concentrations permitted the determination of Michealis-
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Menten kinetic parameters by progress curve analysis (125). As transfection efficiency can 
vary between experiments, the SRD5A1 catalysed conversion of 5µM T to DHT was included 
in each experiment in order to normalise enzyme expression. Using this approach all data sets 
could be compared even though they were generated in separate experiments. The Km value 
for T (Km = 3.73µM) produced in this study is very similar to that obtained in previous studies 
(Km = 3.6µM) (81, 86).  In contrast, the Km obtained for A4 (6.76µM) was not only greater 
than the previously reported value (1.7µM) (81), but also greater than Km values for T. A 
possible reason for the difference in Km values obtained for A4 and T in this study, and those 
of previously reported, is that whole cells were used in the current study, while previous 
studies used cell homogenates with the addition of exogenous NADPH. As cofactors assist in 
the activity of enzymes, increasing or creating an environment in which cofactors are 
unlimited would allow enzymes to perform under optimal conditions, throughout the assay 
period.  However, these conditions may not always be a true reflection of biologically 
relevant concentrations. The whole cell approach thus reflects true cellular concentrations as 
well as the depletion of cofactors resulting from enzymatic activity. The Vmax values acquired 
from this study (A4 = 4.01µM/h and T = 2.05µM/h) relates to a previous study by Andersson 
et al., as Vmax for A4 (1.1 -5.0nmol/(min·mg)) was substantially higher than that for 
testosterone (0.7 - 3.6 nmol/(min·mg)) (81).  
The use of the Vmax/Km ratio is perhaps a more effective way to compare the catalytic 
efficiency of an enzyme towards different substrates (121). These values suggested that 
SRD5A1 has similar catalytic efficiencies towards A4 (0.59) and T (0.55). Our results do, 
however, indicate that T is the preferred substrate at lower substrate concentrations due to the 
higher affinity of the enzyme for this substrate, while A4 is metabolised more efficiently at 
higher substrate concentrations. Under castrate conditions, the concentration of A4 is 
significantly higher (100-fold) than that of T (45) suggesting that A4 will be the preferred 
substrate (46). The results for the 11OHA4 pathway metabolites suggest that the flux through 
this pathway would mirror that of the 5α-dione pathway as SRD5A1 prefers 11OHA4 and 
11KA4 considerably over 11OHT and 11KT. Considering the C11-hydroxy and C11-keto 
steroids, the Km was lowest for 11OHA4 (9.33µM), indicating that SRD5A1 has a greater 
affinity for this substrate over the other metabolites in the 11OHA4 pathway, 11KA4 
(35.20µM), 11OHT (72.06µM) and 11KT (100µM). The Vmax values of these metabolites 
were consistent with the trends observed for the utilisation of the A4 derivatives (11KA4 = 
5.91µM/h and 11OHA4 = 3.07µM/h) over the T derivatives (11KT = 4.84 µM/h and 11OHT 
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= 3.85µM/h).  The catalytic efficiency (Vmax/Km) of 11OHA4 is highest at 0.33, followed by 
11KA4 at 0.17 and finally 0.05 for both 11OHT and 11KT. This indicates that the enzymatic 
activity towards the metabolites in the 11OHA4 pathway is highest towards the A4 
derivatives compared to the T derivatives, as is true for the 5α-dione pathway metabolites 
(46). 11KA4 is a better substrate at higher concentrations which approach Vmax, however, 
SRD5A1 has a ± 2 fold higher catalytic efficiency towards 11OHA4 than towards 11KA4 and 
is likely the preferred substrate under cellular conditions.  
The fitted data and experimental data in the progress curve analyses relate well to one another 
for the metabolites in the 11OHA4 pathway, but the absence of accurate quantification of 
product formation introduces possible errors that could culminate into less accurate kinetic 
parameters. The 11OHT and 11KT experimental and theoretical data seem to be the least well 
fitted, thus Km values obtained here are preliminary results and could be the improved if the 
novel steroids were available. The Km obtained for 11KA4 by progress curve analysis is 
substantially higher (3.8-fold) than that of 11OHA4 although the substrate utilisation trends 
are similar, perhaps suggesting that more accurate kinetic parameters can be obtained during 
future optimisations. Furthermore, future studies should be performed to investigate the 
ability of the current kinetic parameters to predict the metabolism of C19 substrates at various 
starting concentrations and with multiple starting substrate combinations. Such experiments 
will serve as a validation of the current kinetic model. Since the completion of this project 
11KDHT has become available, but no quantitative analyses have been carried out with this 
steroid to date.        
A second approach to overcome the unavailability of commercial standards is to use the 
SRD5A1 enzyme as a biocatalyst to produce sufficient quantities of the novel steroids for 
analytical purposes. A yeast expression system, P. pastoris, was therefore chosen to express 
functional SRD5A1 protein with the aim of facilitating purification of the enzyme and 
developing a biocatalyst for the production of novel C19 androgens. The GS115 strain is 
histidinol dehydrogenase deficient (114), which is exploited in the selection of positive 
transformants, as the pPIC3.5K vector introduces a selectable marker, HIS4, a gene which 
encodes histidine biosynthesis. An added selectable marker introduced to the genome of the 
positively transformed yeast is the Tn903kan
r
 gene (Kanamycin resistant gene), which 
translates to a resistance to G418 in P. pastoris that proportionally increases with increase in 
copy number integration (119). In this study, SRD5A1 was successful cloned into the yeast 
expression vector and transformation of the yeast was accomplished using the PEG/LiCl 
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method. Two rounds of selection were carried out, favouring multicopy transformants due to 
the high expression rates. Transformants which possess the ability to produce histidine, as a 
result of plasmid integration (HIS4), were pooled post selection on medium lacking histidine 
and subjected to increasing concentrations of G418 containing YPD-agar plates. Positive 
transformants, able to resist concentrations of 0.25, 0.5, 0.75 and 1.0 mg/ml G418, were 
subjected to a crude DNA extraction and subsequent PCR of the genomic DNA as 
confirmation of the integration of the gene into yeast genome. This also allowed for the 
estimation of the copy number incorporated. The selection on G418 plates coupled to the PCR 
results indicated that a single copy number was obtained for the transformant S 0.25, while 
copy numbers of two were achieved for the transformants S 0.5, S 0.75 and S1.0.  
Copy number integration does not, however, always guarantee the more efficient expression 
of a protein. A simple conversion assay was therefore employed in this study in order to select 
the transformants with the highest SRD5A1 activity. The transformant S 1.0 and S 0.75 
demonstrated the highest SRD5A1 activity, correlating to the copy number determinations, 
with S 0.75 demonstrating marginally higher SRD5A1 activity. Furthermore, expression of 
SRD5A1 was shown not to effect the growth of the yeast during the induction phase. This 
study therefore marks the first report of the functional expression of a human SRD5A enzyme 
in the methalotophic yeast P. Pastoris.   
A previous study demonstrated the endogenous expression of HSD3A or HSD3B in the yeast 
S. cerevisiae as this yeast was capable of converting the 5α-reduced steroid DHT to 3α-adiol 
or 3β-adiol (75). HSD3A/B activity has not previously been investigated in P. pastoris and 
was therefore explored in this study. Untransformed, methanol induced P. pastoris were 
incubated with the Δ4 steroids, 11OHA4, 11KA4, 11OHT, 11KT and T as well as the 5α-
reduced steroid DHT. While no conversion of the Δ4 steroids was observed, DHT was 
completely metabolised, indicating probable HSD3A/B activity in the yeast.  
This endogenous activity would be a hindrance for the production of the novel 5α-reduced 
steroids as these steroids would potentially serve as substrates for the endogenous enzymatic 
activity. An ideal solution would therefore be to purify SRD5A1 from the yeast cells. 
However, due to the unstable nature of the membrane bound microsomal proteins, neither 
human isoenzyme has been purified in their active form to date (8). The elimination of the 
endogenous enzymatic activity may, however, be achieved by fractionating the yeast in order 
to compartmentalise the SRD5A1. SRD5A1 is expressed in the ER, while HSD is likely 
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cytosolic. Microsomes could therefore be prepared to obtain SRD5A1 activity in the absence 
of HSD activity. This approach will be further investigated in future studies. It was, however, 
first important to confirm that SRD5A1 expressed in the yeast demonstrated sufficient activity 
towards the hydroxyl and keto derivatives of A4 and T, if this system is to be used as a 
biocatalyst in future. The metabolism of metabolites in the 5α-dione and 11OHA4 pathways 
was therefore investigated and the activity of SRD5A1 expressed in yeast was comparable to 
the activity of SRD5A1 expressed in a mammalian system.  
A4 and T metabolism displayed the same trends as seen in the HEK-293 cells (5µM, figure 
3.3) as well as in previous studies (86), with the utilisation of A4 being preferred over that of 
T. A4 (30µM) and T (30µM) were metabolised within 2 hours and 4 hours, respectively by P. 
pastoris expressing SRD5A1. This data, obtained under substrate saturating conditions, is in 
agreement with the 2-fold difference in Vmax value obtained from the progress curve analysis 
studies performed in HEK-293 cells (table 3.3).  
Furthermore, the conversion of the metabolites in the 11OHA4 pathway by SRD5A1 
expressed in the yeast system correlated to trends observed in the mammalian expression 
system, with the enzyme demonstrating a preference for the A4 derivatives over the T 
derivatives. The yeast system thus proved to be a viable alternative in studying the enzymatic 
activities of mammalian enzymes. The unmodified human steroidogenic enzyme CYP17A1, 
was first expressed in its functional form to allow for characterisation of the enzyme in this 
yeast system (109). P. pastoris has also been used for the heterologous expression of vast 
ranges of bacterial (126) and human (109) proteins, which include intracellular (127) and 
secreted proteins (128).  
Conversion of the C11 hydroxy and C11 keto 5α-reduced steroids by the endogenous 
HSD3A/B was also observed in this study. Interestingly though, the 5α-reduced A4 products 
(11OH-5α-dione, 11K-5α-dione and 5α-dione) were found to accumulate prior to utilisation 
by the endogenous enzyme, while the 5α-reduced T products (11OHDHT, 11KDHT and 
DHT) were rapidly metabolised by the endogenous enzyme demonstrating that the 
endogenous enzyme prefers the 5α-reduced T derivatives over the A4 derivatives. The yeast 
model therefore provides further evidence that 5α-reduced metabolites of the 11OHA4 
pathway are capable of being packaged for elimination. HSD3A/B catalyses the conversion of 
active androgen to weak androgens, which are subsequently glucoronidated or sulphonated 
for elimination (94).  HSD3A is thought to be the endogenous enzyme expressed in P. 
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pastoris as evidence of AST formation was observed when A4 was incubated with yeast 
expressing SRD5A1. Investigations into the inactivation of 5α-reduced C19 steroids by 
HSD3A and subsequently glucoronidation in the model CRPC cell line LNCaP uncovered an 
extension to the 11OHA4 pathway. Swart and Storbeck recently proposed that 11OHDHT 
and 11KDHT are substrates for HSD3A, yielding 11OH-3α-atriol and 11K-3α-adiol, 
respectively. Although they were only able to show the metabolism of 11KDHT by human 
HSD3A, this study provides evidence that both 11OHDHT and 11KDHT are metabolised by 
endogenous HSD3A in P. pastoris. Swart and Storbeck have also demonstrated that 11OH-
5α-dione and 11K-5α-dione are substrates for human HSD3A, yielding 11OHAST and 
11KAST, respectively (129). In this study we found that while 11OH-5α-dione and 11K-5α-
dione were substrates for endogenous HSD3A, this yeast enzyme preferred 5α-reduced T 
derivatives. In the prostate the A4 derivatives are only glucuronidated/sulphonated and 
eliminated once HSD3A has metabolised them, the accumulation of these metabolites in the 
CRPC tumour environment may therefore elicit unfavourable receptor driven responses.    
In conclusion, charactering SRD5A1, in conjunction with other enzymes involved in the 5α-
dione and 11OHA4 pathways, requires innovative approaches as the 5α-reduced steroids 
produced in this pathway are not commercially available. Incorporating response factors thus 
far has yielded good results which allowed for the characterisation of SRD5A1 in HEK-293 
cells. The accuracy and linearity of these response factors could be confirmed in future by 
repeating the experiments using multiple starting concentrations. The best method would, 
however, be to produce sufficient quantities of the steroids, using a biocatalyst, as to facilitate 
their extraction and purification. This study has shown that the yeast expression system is a 
strong candidate for achieving high yields of active enzyme which can be either purified or 
studied in its cellular environment in microsomal preparations. Higgins and Cregg previously 
stated that the biggest hurdle with regards to heterologous protein expression in yeast systems 
is achieving initial success, with the expression of protein at any level considered as such 
(106). This objective was successfully achieved in this study, the first in which the expression 
of functional human SRD5A1 in P. pastoris has been reported. 
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